

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|----|--|
| (51) International Patent Classification 6 : C07C 225/22, A61K 31/135 | A1 | (11) International Publication Number: WO 98/32730 (43) International Publication Date: 30 July 1998 (30.07.98) |
|--|----|--|

(21) International Application Number: PCT/DK98/00008

(22) International Filing Date: 8 January 1998 (08.01.98)

(30) Priority Data:
9701453.4 24 January 1997 (24.01.97) GB

(71) Applicant (for all designated States except US): LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) [DK/DK]; Industriparken 55, DK-2750 Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): OTTOSEN, Erik, Rytter [DK/DK]; Lotusvej 6, DK-3650 Ølstykke (DK). RACHLIN, Schneur [DK/DK]; Slotsbakken 125, DK-2970 Hørsholm (DK).

(74) Agent: KRISTENSEN, Per, Rydahl; Leo Pharmaceutical Products Ltd. A/S, Patent Dept., Industriparken 55, DK-2750 Ballerup (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(54) Title: AMINOBENZOPHENONES AS INHIBITORS OF INTERLEUKIN AND TNF

(57) Abstract

The compounds of the present invention are represented by general formula (I) in which formula R_1 and R_2 stand independently for one or more, similar or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, cyano, carboxy, carbamoyl, phenyl, or nitro; R_3 stands for hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, phenyl, cyano, carboxy, or carbamoyl; R_4 , R_5 and R_6 stand independently for hydrogen, trifluoromethyl, alkyl, carbamoyl, alkoxycarbonyl, or alkoxylo, the C-content of which can be from 1 to 5; X stands for oxygen, N-OH, N-O-alkyl, dialkoxo, cyclic dialkoxo, dialkylthio, or cyclic dialkylthio, the C-content of which can be from 1 to 5. The present compounds are of value in the human and veterinary practice as systemic and topical therapeutic agents for the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, proliferative and inflammatory skin disorders, such as psoriasis, and atopic dermatitis.



(I)

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | KR | Republic of Korea | PL | Poland | | |
| CN | China | KZ | Kazakhstan | PT | Portugal | | |
| CU | Cuba | LC | Saint Lucia | RO | Romania | | |
| CZ | Czech Republic | LI | Liechtenstein | RU | Russian Federation | | |
| DE | Germany | LK | Sri Lanka | SD | Sudan | | |
| DK | Denmark | | | SE | Sweden | | |

AMINO BENZOPHENONES AS INHIBITORS OF INTERLEUKIN AND TNF

This invention relates to a hitherto unknown class of compounds which shows anti-inflammatory effects, to pharmaceutical preparations containing these compounds, to dosage units of such preparations, and to their use in the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, proliferative and inflammatory skin disorders, such as psoriasis, and atopic dermatitis.

The compounds of the present invention are represented by the general formula I



I

in which formula R_1 and R_2 stands independently for one or more, similar or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, and alkoxycarbonyl, the C-content of which can be from 1 to 5, cyano, carboxy, carbamoyl, phenyl, or nitro; R_3 stand for hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxycarbonyl, the C-content of which can be from 1 to 5, phenyl, cyano, carboxy, or carbamoyl; R_4 , R_5 and R_6 stands independently for hydrogen, trifluoromethyl, alkyl, carbamoyl, alkoxycarbonyl, or alkyloxy, the C-content of which can be from 1 to 5; X stands for oxygen, N-OH, N-O-alkyl, dialkoxy, cyclic dialkoxy, dialkylthio, or cyclic dialkylthio, the C-content of which can be from 1 to 5.

The compounds can be used in the form of their salts which are formed with pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, hydrobromic and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, butyric acid, valeric acid, stearic acid, palmitic acid, myristic acid, lauric acid, capric acid, caproic acid, succinic acid, malic acid, tartaric acid, citric acid, fumaric acid, maleic acid, phthalic acid, benzoic acid, salicylic acid, lactic acid, pyruvic acid, oxalic acid, and carbonic acid.

toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid, maleic acid, these examples being considered as non-limiting for the invention.

Previously, a series of closely related aminobenzophenones (e.g. 4-(2-amino-4-nitrophenylamino)benzophenone) have been described (Hussein, F.A. *et al*, Iraqi J. Sci., 22, 54-66 (1981)). However, there is no description of their uses.

Now we have surprisingly found that novel aminobenzophenones according to general formula I are potent inhibitors of interleukin 1β (IL- 1β) and tumour necrosis factor α (TNF- α) secretion *in vitro*, making them potentially useful for treatment of inflammatory diseases, in which the production of cytokines is involved in the pathogenesis, e.g. asthma, rheumatoid arthritis, psoriasis, contact dermatitis, and atopic dermatitis.

To study the effect of the compound of the present invention, *in vitro*, the inhibition of the IL- 1β and TNF- α secretion was measured using the following procedure:

Cytokine production was measured in the media from lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells. The mononuclear cells were isolated from human peripheral blood by Lymphoprep[®] (Nycomed, Norway) fractionation and suspended in RPMI 1640 (growth medium) with foetal calf serum (FCS, 2%), at a concentration of 5×10^5 cells/ml. The cells were incubated in 24-well tissue culture plates in 1 ml aliquots. Test compounds were dissolved in dimethylsulfoxide (DMSO, 10 mM) and were diluted with the medium. Compounds were added to the cells for 30 minutes, then LPS (1 μ g/ml final concentration) was added. The plates were incubated for 18 hours, and the concentration of IL- 1β and TNF- α in the medium was determined by enzyme-linked immunosorbent assays. The median inhibitory concentrations (IC₅₀) of the compounds were calculated. The results are shown in table 1.

The compounds of the present invention also show similar activities in the ability to inhibit PMN (polymorphonuclear) superoxide secretion which is also indicative of potentially useful anti-inflammatory drugs. The compounds were tested using the following procedure:

Human polymorphonuclear (PMN) granulocytes were isolated from human blood by dextran sedimentation, Lymphoprep® fractionation and hypotonic lysis of contaminating erythrocytes.

Superoxide anion generation was measured as the superoxide dismutase inhibitable reduction of ferricytochrome C (Madhu, S.B. et al, Inflammation, 16, 241, (1992)).

The cells were suspended in Hanks' balanced salt solution, and incubated for 10 minutes at 37°C with test compounds. The cells were primed by the addition of TNF- α (3 ng/ml final concentration) for 10 minutes, and then ferricytochrome C, (final concentration 750 μ g/ml), bovine serum albumin (BSA, final concentration 1 mg/ml) and formyl-methionyl-leucyl-phenylalanine (fMLP, final concentration 10⁻⁷ M) were added for 3 minutes.

The cells were chilled on ice, and were spun down. The optical densities in the cell-free supernatant was measured in a spectrophotometer.

The median inhibitory concentration (IC₅₀) of the compounds was calculated. The results are shown in Table 1.

Table 1. Inhibition of cytokines and PMN-superoxide production *in vitro* by compounds of the following examples of the present invention.

| Compound from | The median inhibition concentration (IC ₅₀ , nM) of | | |
|----------------|--|---------------|----------------|
| | IL-1 β | TNF- α | PMN-superoxide |
| Example no. 1 | 250 | 790 | 160 |
| Example no. 13 | 160 | 200 | 40 |
| Example no. 32 | 100 | 130 | > 10000 |
| Example no. 56 | 13 | 7.1 | 5.0 |
| Example no. 73 | 32 | 5.0 | 5.0 |

These results show that the compounds of the present invention are able to inhibit the production of IL-1, TNF- α and PMN-superoxide, thus making them potentially

To study the compounds of the present invention *in vivo* the 12-*O*-tetradecanoylphorbol-13-acetate (TPA) induced murine chronic skin inflammation model were used (De Young, L.M. et al, Agents Actions, 26, 335-341 (1989); Carlson, R.P. et al, Agents Actions, 17, 197-204 (1985); Alford, J.G. et al, Agents Action, 37, (1992); Stanley, P.L. et al, Skin Pharmacol, 4, 262-271 (1991)). The compounds were tested using the following procedure:

In groups of 6 female mice weighing 18-25 grams, ear skin inflammation was induced by multiple topical applications of TPA on alternate days during a 10 day period. The resulting inflammation was treated topically with compounds in acetone (20 μ l/ear) twice daily on day 8, 9 and 10 and once on day 11. The increased ear thickness (ET, right ear thickness minus left ear thickness) was determined approximately 6 hours after the treatment, the mice were sacrificed and the myeloperoxidase (MPO)-activity was determined in ear biopsies. The results are shown in Table 2.

Table 2. Effect in the TPA induced murine skin inflammation model by compounds of the following examples of the present invention.

| Compound from | Dose (mg/ear) | % inhibition of ET | % inhibition of MPO |
|----------------|------------------|--------------------|---------------------|
| Example no. 1 | 0.1 | 50 | 65 |
| Example no. 2 | 0.1 | 40 | 76 |
| Example no. 27 | 0.1 | 44 | 48 |
| Hydrocortisone | 0.1 ^a | 58 | 69 |
| | 0.03 | 36 | 51 |


a) Reduction of spleen and thymus weight.

These results shows that the compounds of the present invention are of the same potency compared to known reference compounds, e.g. hydrocortisone with its known side effects, whereas the compounds of the present invention are well tolerated and are non-toxic. Some members of the present class of compounds show a very low

dermatological diseases. In general, they may be administered by oral, intravenous, interperitoneal, intranasal, topically or transdermal routes.

The present invention also relates to methods for preparing the desired compounds of the general formula I. The compounds of the formula I may conveniently be prepared by standard procedures detailed in the art. The routes are outlined in the following reaction scheme.

Scheme 1: Synthesis of the compounds of the general formula I



Notes to scheme 1

- a) Potassium tert-butoxide / dimethylsulfoxide / 20 °C / 24-60 hours
- 5 b) Hydrazine hydrate / 10% Pd/C / ethanol / 20 °C / 24 hours
or
Stannous chloride dihydrate / ethanol / 70 °C / 1-4 hours
- c) Alkyl- or aryl-sulfonyl chloride / pyridine / 20 °C / 60-120 min
- 10 d) Alkyl halogenide / potassium carbonate / *N,N*-dimethylformamide / 20 °C /
96 hours
- e) Acetic anhydride / 20 °C / 3 hours
- 15 f) Alkyl- or aryl-isocyanate / toluene / 100 °C / 20 hours
- g) Alkyl- or aryl-chloroformate / potassium carbonate / *N,N*-
dimethylformamide / 20 °C / 96 hours
- 20 h) Hydroxylamine hydrochloride / ethanol / sodium acetate / reflux / 20 °C /
30 hours
- i) *O*-Methylhydroxylamine hydrochloride / ethanol / sodium acetate / reflux /
20 °C / 25 hours

The present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of the above mentioned diseases.

The amount required of a compound of formula I (hereinafter referred to as the active ingredient) for therapeutic effect will, of course, vary both with the particular
5 compound, the route of administration and the mammal under treatment. A suitable dose of a compound of formula I for systemic treatment is 0.1 to 200 mg/kg bodyweight, the most preferred dosage being 0.2 to 50 mg/kg of mammal bodyweight, administered one or more times daily.

While it is possible for an active ingredient to be administered alone as the raw
10 chemical, it is preferable to present it as a pharmaceutical formulation. Conveniently, the active ingredient comprises from 0.1% to 100% by weight of the formulation. Conveniently, dosage units of a formulation contain between 0.07 mg and 1 g of the active ingredient. For topical administration, the active ingredient preferably comprises from 1% to 20% by weight of the formulation but the active ingredient may comprise as
15 much as 50% w/w. Formulations suitable for nasal or buccal administration may comprise 0.1% to 20% w/w. for example about 2% w/w of active ingredient.

By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active
20 material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.

The formulations, both for veterinary and human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the
25 formulations and not deleterious to the recipient thereof.

The formulations include those in a form suitable for oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), transdermal, intra-articular, topical, nasal, or buccal administration.

The formulations may conveniently be presented in dosage unit form and may be
30 prepared by any of the methods well known in the art of pharmacy. All methods include

tutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

5 Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient
10 may also be administered in the form of a bolus, electuary or paste.

 Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.

 Formulations suitable for parenteral administration conveniently comprise a
15 sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.

 Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal
20 formulations or biodegradable polymer systems may also be used to present the active ingredient for both intra articular and ophthalmic administration.

 Formulations suitable for topical administration, including eye treatment, include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or
25 suspensions such as drops.

 Formulations suitable for administration to the nose or buccal cavity include powder, self-propelling and spray formulations, such as aerosols and atomizers.

 In addition the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients.

30 The compositions may further contain other therapeutically active compounds

instance glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines, β -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin
5 (Salazopyrin).

The invention will now be further described in the following non-limiting general procedures, preparations and examples:

General procedures, preparations and examples

The exemplified compounds I are listed in table 3, whereas compounds of the
10 general formula II are listed in table 4

All melting points are uncorrected. For ^1H and ^{13}C nuclear magnetic resonance (NMR) spectra (300 MHz) chemical shift values (δ) are quoted, unless otherwise specified, for deuteriochloroform and hexadeuterodimethylsulfoxide solutions relative to internal tetramethylsilane (δ 0.00) or chloroform (^1H NMR δ 7.25, ^{13}C NMR δ 76.81).
15 The value for a multiplet (m), either defined (doublet (d), triplet (t), quartet (q)) or not at the approximate mid point is given unless a range is quoted (s singlet, b broad).
Chromatography was performed on silica gel.

e3

| ip. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|-----|-------------|-----------------|--|---|----------------|----------------|-------------------|----------------|----------------|----------------|
| | 1 | I | 2 | O | H | H | H | H | H | H |
| | 2 | I | 4 | O | H | H | H | H | H | H |
| | 3 | I | 2 | O | H | H | 4-Me | H | H | H |
| | 4 | I | 2 | O | H | H | 4-CF ₃ | H | H | H |
| | 5 | I | 2 | O | H | H | 4-COOH | H | H | H |
| | 6 | I | 4 | O | H | H | 2-CN | H | H | H |
| | 7 | I | 4 | O | H | H | 2-COOH | H | H | H |
| | 8 | I | 4 | O | H | H | 2-Me | H | H | H |
| | 9 | I | 2 | O | 2-F | H | H | H | H | H |
| | 10 | I | 2 | O | 4-F | H | H | H | H | H |
| | 11 | I | 2 | O | 4-t-Bu | H | H | H | H | H |
| | 12 | I | 2 | O | 3-F | H | H | H | H | H |
| | 13 | I | 2 | O | 2-Cl | H | H | H | H | H |
| | 14 | I | 2 | O | 3-Cl | H | H | H | H | H |

le 3 (continued)

| Ex. No. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|---------|-------------|-----------------|--|---|------------------------------|-------------------|----------------|-------------------------|----------------|----------------|
| 15 | I | | 2 | O | 2-OMe | H | H | H | H | H |
| 16 | I | | 2 | O | 3-N(Me) ₂ | H | H | H | H | H |
| 17 | I | | 2 | O | 4-Cl | H | H | H | H | H |
| 18 | I | | 2 | O | 3-Me | H | H | H | H | H |
| 19 | I | | 4 | O | H | 3-NH ₂ | H | H | H | H |
| 20 | I | | 2 | O | 4-n-pentyl | H | H | H | H | H |
| 21 | I | | 2 | O | 4-Cl; 2-SCH(Me) ₂ | H | H | H | H | H |
| 22 | I | | 2 | O | 4-CF ₃ | H | H | H | H | H |
| 23 | I | | 2 | O | H | H | H | SO ₂ Et | H | H |
| 24 | I | | 2 | O | H | H | H | SO ₂ Ph | H | H |
| 25 | I | | 4 | O | H | H | H | SO ₂ Me | H | H |
| 26 | I | | 2 | O | H | H | H | SO ₂ Me | H | H |
| 27 | I | | 2 | O | H | H | H | SO ₂ Ph-4-Me | H | H |

a3 (continued)

| P. No. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|--------|-------------|-----------------|--|-------|--------------------------------------|----------------|----------------|-----------------------|----------------|----------------|
| 28 | I | | 2 | O | H | H | H | CONHPh | H | H |
| 29 | I | | 2 | O | H | H | H | Ac | H | H |
| 30 | I | | 2 | N-OH | H | H | H | H | H | H |
| 31 | I | | 2 | N-OMe | H | H | H | H | H | H |
| 32 | I | | 2 | O | H | H | H | COOEt | H | H |
| 33 | I | | 2 | O | H | H | H | CH ₂ COOEt | H | H |
| 34 | I | | 2 | O | H | H | H | Me | H | H |
| 35 | I | | 2 | O | H | H | H | Me | Me | H |
| 36 | I | | 2 | O | 3,4,5-tri-OMe | H | H | H | H | H |
| 37 | I | | 2 | O | H | H | H | H | H | Me |
| 38 | I | | 2 | O | 2-Me | H | H | H | H | H |
| 39 | I | | 2 | O | 3,4 (OCH ₂) ₂ | H | H | H | H | H |
| 40 | I | | 2 | O | 4-Cl | 2-Cl | H | H | H | H |

e 3 (continued)

| p. No. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|--------|-------------|-----------------|--|---|----------------------------|----------------|----------------|----------------|----------------|----------------|
| 41 | I | | 2 | O | 2,4-di-Cl | H | H | H | H | H |
| 42 | I | | 2 | O | 4-(1-methyl-butyl- oxy) | H | H | H | H | H |
| 43 | I | | 2 | O | 3-CF ₃ | H | H | H | H | H |
| 44 | I | | 2 | O | 2,3-di-OMe | H | H | H | H | H |
| 45 | I | | 2 | O | 3-n-BuO | H | H | H | H | H |
| 46 | I | | 2 | O | 4-OEt | H | H | H | H | H |
| 47 | I | | 2 | O | 3,5-di-Cl | H | H | H | H | H |
| 48 | I | | 2 | O | 4-OCH ₂ Ph | H | H | H | H | H |
| 49 | I | | 2 | O | 3-OMe, 4-Me | H | H | H | H | H |
| 50 | I | | 4 | O | H | H | 2-Cl | H | H | H |
| 51 | I | | 2 | O | 4-OMe | H | H | H | H | H |
| 52 | I | | 2 | O | H | 2-Cl | H | H | H | H |
| 53 | I | | 2 | O | H | 3-Me | H | H | H | H |

e 3 (continued)

| p. No. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|--------|-------------|-----------------|--|---|-----------------------|----------------|----------------|----------------|----------------|----------------|
| 54 | I | | 2 | O | 3-Ph | H | H | H | H | H |
| 55 | I | | 2 | O | 2-Ph | H | H | H | H | H |
| 56 | I | | 2 | O | 2-Me | 2-Cl | H | H | H | H |
| 57 | I | | 2 | O | 4-Ph | H | H | H | H | H |
| 58 | I | | 2 | O | H | H | 5-OH | H | H | H |
| 59 | I | | 2 | O | 2-OH | H | H | H | H | H |
| 60 | I | | 4 | O | 2-Me | H | H | H | H | H |
| 61 | I | | 2 | O | 3-CN | H | H | H | H | H |
| 62 | I | | 2 | O | 2-CH ₂ OPh | H | H | H | H | H |
| 63 | I | | 2 | O | 2-Br | H | H | H | H | H |
| 64 | I | | 2 | O | 2,3,5,6-tetra-Me | H | H | H | H | H |
| 65 | I | | 2 | O | 2-Et | H | H | H | H | H |
| 66 | I | | 3 | O | H | H | H | H | H | H |

e 3 (continued)

| p. No. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|--------|-------------|-----------------|--|---|-------------------|----------------|----------------|----------------|----------------|----------------|
| 67 | I | | 4 | O | 2-OH | H | H | H | H | H |
| 68 | I | | 2 | O | 2-Me | 3-Me | H | H | H | H |
| 69 | I | | 2 | O | 2-Me | 3-OMe | H | H | H | H |
| 70 | I | | 2 | O | 2-Me | 2-OMe | H | H | H | H |
| 71 | I | | 2 | O | 2-t-BuO | H | H | H | H | H |
| 72 | I | | 2 | O | 2-CF ₃ | 2-Cl | H | H | H | H |
| 73 | I | | 2 | O | 2-Me | 2-Cl | H | COOEt | H | H |
| 74 | I | | 2 | O | 2,6-di-Me, 4-OMe | 2-Cl | H | H | H | H |
| 75 | I | | 4 | O | 2-Me | 2-Cl | H | H | H | H |
| 76 | I | | 2 | O | 2-O-allyl | H | H | H | H | H |
| 77 | I | | 2 | O | 2-Me | 2-Cl | 4-Me | H | H | H |
| 78 | I | | 2 | O | 2-OMe | 2-Cl | H | H | H | H |
| 79 | I | | 2 | O | 2-OH, 3-allyl | H | H | H | H | H |

e 3 (continued)

| p. No. | Example No. | General formula | Position of NR ₄ R ₅ | X | R ₁ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ |
|--------|-------------|-----------------|--|---|----------------|----------------|----------------|--------------------|----------------|-------------------|
| 80 | I | | 2 | O | 2,4,5-tri-F | 2-Cl | H | H | H | H |
| 81 | I | | 2 | O | 2-Me | 2-Cl | H | COCF ₃ | H | H |
| 82 | I | | 2 | O | 2,6-di-Me | 2-Cl | H | H | H | H |
| 83 | I | | 2 | O | 2-Me, 4-F | 2-Cl | H | H | H | H |
| 84 | I | | 2 | O | 2-Me | 2-Cl | H | CONMe ₂ | H | H |
| 85 | I | | 2 | O | H | H | H | n-butyl | H | H |
| 86 | I | | 2 | O | H | H | H | COCF ₃ | H | COCF ₃ |
| 87 | I | | 2 | O | H | H | H | COCF ₃ | H | H |
| 88 | I | | 2 | O | H | H | H | CONHpropyl | H | H |
| 89 | I | | 2 | O | H | H | H | COH | H | H |

| p. | Prep. No. | General formula | Position of NO ₂ | X | R ₁ | R ₂ | R ₃ | R ₆ |
|----|-----------|--------------------|--------------------------------|---|----------------|----------------|-------------------|----------------|
| 1 | | II | 2 | O | H | H | H | H |
| 2 | | II | 4 | O | H | H | H | H |
| 3 | | II | 2 | O | H | H | 4-Me | H |
| 4 | | II | 2 | O | H | H | 4-CF ₃ | H |
| 5 | | II | 2 | O | H | H | 4-COOH | H |
| 6 | | II | 4 | O | H | H | 2-CN | H |
| 7 | | II | 4 | O | H | H | 2-COOH | H |
| 8 | | II | 4 | O | H | H | 2-Me | H |
| 9 | | II | 2 | O | 2-F | H | H | H |
| 10 | | II | 2 | O | 4-F | H | H | H |
| 11 | | II | 2 | O | 4-t-Bu | H | H | H |
| 12 | | II | 2 | O | 3-F | H | H | H |
| 13 | | II | 2 | O | 2-Cl | H | H | H |
| 14 | | II | 2 | O | 3-Cl | H | H | H |

e 4 (continued)

| p. | Prep. No. | General formula | Position of NO ₂ | X | R ₁ | R ₂ | R ₃ | R ₆ |
|----|-----------|-----------------|-----------------------------|---|--------------------------------------|-------------------|----------------|----------------|
| 15 | II | | 2 | O | 2-OMe | H | H | H |
| 16 | II | | 2 | O | 3-N(Me) ₂ | H | H | H |
| 17 | II | | 2 | O | 4-Cl | H | H | H |
| 18 | II | | 2 | O | 3-Me | H | H | H |
| 19 | II | | 4 | O | H | 3-NO ₂ | H | H |
| 20 | II | | 2 | O | 4-n-pentyl | H | H | H |
| 21 | II | | 2 | O | 4-Cl; 2-SCH(Me) ₂ | H | H | H |
| 22 | II | | 2 | O | 4-CF ₃ | H | H | H |
| 23 | II | | 2 | O | 3,4,5-tri-OMe | H | H | H |
| 24 | II | | 2 | O | H | H | H | Me |
| 25 | II | | 2 | O | 2-Me | H | H | H |
| 26 | II | | 2 | O | 2,4-di-Cl | H | H | H |
| 27 | II | | 2 | O | 3,4-(OCH ₂) ₂ | H | H | H |

e 4 (continued)

| ip. | Prep. No. | General formula | Position of NO ₂ | X | R ₁ | R ₂ | R ₃ | R ₆ |
|-----|-----------|-----------------|-----------------------------|---|----------------------------|----------------|----------------|----------------|
| 28 | II | | 2 | O | 4-Cl | 2-Cl | H | H |
| 29 | II | | 2 | O | 4-(1-methyl-butyl- oxy) | H | H | H |
| 30 | II | | 2 | O | 2,3-di-OMe | H | H | H |
| 31 | II | | 2 | O | 3-n-BuO | H | H | H |
| 32 | II | | 2 | O | 3-CF ₃ | H | H | H |
| 33 | II | | 2 | O | 3,5-di-Cl | H | H | H |
| 34 | II | | 2 | O | 4-OCH ₂ Ph | H | H | H |
| 35 | II | | 2 | O | 4-OEt | H | H | H |
| 36 | II | | 4 | O | H | H | 2-Cl | H |
| 37 | II | | 2 | O | 3-OMe, 4-Me | H | H | H |
| 38 | II | | 2 | O | H | 2-Cl | H | H |
| 39 | II | | 2 | O | 4-OMe | H | H | H |
| 40 | II | | 2 | O | H | 3-Me | H | H |
| 41 | II | | 2 | O | 2-Ph | H | H | H |

p. 4 (continued)

| p. | Prep. No. | General formula | Position of NO ₂ | X | R ₁ | R ₂ | R ₃ | R ₆ |
|----|-----------|-----------------|-----------------------------|---|-----------------------|----------------|----------------|----------------|
| 42 | II | | 2 | O | 3-Ph | H | H | H |
| 43 | II | | 2 | O | 2-Me | 2-Cl | H | H |
| 44 | II | | 2 | O | 3-CN | H | H | H |
| 45 | II | | 2 | O | 4-Ph | H | H | H |
| 46 | II | | 4 | O | 2-Me | H | H | H |
| 47 | II | | 2 | O | 2-OH | H | H | H |
| 48 | II | | 2 | O | 2-Et | H | H | H |
| 49 | II | | 2 | O | 2-CH ₂ OPh | H | H | H |
| 50 | II | | 2 | O | 2-Br | H | H | H |
| 51 | II | | 2 | O | 2,3,5,6-tetra-Me | H | H | H |
| 52 | II | | 2 | O | 2-Me | 3-OMe | H | H |
| 53 | II | | 2 | O | 2-Me | 3-Me | H | H |
| 54 | II | | 2 | O | 2-O-allyl | H | H | H |
| 55 | II | | 2 | O | 2-Me | 2-OMe | H | H |

e 4 (continued)

| p. | Prep. No. | General formula | Position of NO ₂ | X | R ₁ | R ₂ | R ₃ | R ₆ |
|----|-----------|--------------------|--------------------------------|---|-------------------|----------------|----------------|----------------|
| 56 | II | | 2 | O | 2-t-BuO | H | H | H |
| 57 | II | | 2 | O | 2-CF ₃ | 2-Cl | H | H |
| 58 | II | | 2 | O | 3-allyl, 2-OH | H | H | H |
| 59 | II | | 2 | O | 2,6-di-Me, 4-OMe | 2-Cl | H | H |
| 60 | II | | 2 | O | 2-Me | 2-Cl | 4-Me | H |
| 61 | II | | 4 | O | 2-Me | 2-Cl | H | H |
| 62 | II | | 2 | O | 2-OMe | 2-Cl | H | H |
| 63 | II | | 2 | O | 2,4,5-tri-F | 2-Cl | H | H |
| 64 | II | | 2 | O | 2,6-di-Me | 2-Cl | H | H |
| 65 | II | | 2 | O | 2-Me, 4-F | 2-Cl | H | H |
| 66 | II | | 2 | O | H | H | 5-OH | H |

General procedure 1:Coupling of compounds of the general formula III
with compounds of the general formula IVa or IVb to
compounds of the general formula II

5 To a solution of a compound with the general formula III (50 mmol) and a compound with the general formula IVa or IVb (50 mmol) in DMSO (250 ml) was added potassium tert-butoxide (125 g, 110 mmol). The reaction mixture was stirred at room temperature for 24 hours, diluted with water (2.5 l) and acidified with vigorous stirring to pH 5-6 by the addition of acetic acid (100 ml, 3 M). The reaction mixture was cooled and stirred for 12 hours, filtered off and washed with water.

10 The precipitate was dried and purified by recrystallization from an appropriate solvent to give a compound of the general formula II.

General procedure 2:Coupling of compounds of the general formula III
with compounds of the general formula IVa or IVb to
compounds of the general formula II

15 To a solution of a compound with the general formula III (10 mmol) and a compound with the general formula IVa or IVb (10 mmol) in DMSO (25 ml) was added potassium tert-butoxide (2.36 g, 21 mmol). The reaction mixture was stirred at room temperature for 40 hours, diluted with water (300 ml) and extracted with ethyl acetate (3x100 ml). The organic phase was dried (MgSO₄), filtered and evaporated to afford the crude product. The crude product was further purified either by crystallization or flash chromatography to yield the title compound.

General procedure 3:Reduction of compounds of the general formula II to
the corresponding compounds of the general formula
I by treatment with hydrazine hydrate

25 To a suspension of a compound with the general formula II (30 mmol) in ethanol (300 ml) was added, under argon, hydrazine hydrate (99 %, 3.0 ml, 60 mmol) and 10 % palladium on carbon (3.0 g). The reaction mixture was stirred at room temperature for 24 hours. The mixture was filtered through Celite® and treated with

30

precipitate was dried and purified by recrystallization from an appropriate solvent to give a compound of the general formula I.

5 General procedure 4: Reduction of compounds of the general formula II to the corresponding compounds of the general formula I by treatment with stannous chloride dihydrate

A mixture of a compound with the general formula II (5 mmol) and stannous chloride dihydrate (5.64 g, 25 mmol) in absolute ethanol (50 ml) was heated to 70 °C under argon. After 1 hour the starting material has disappeared and the solution was
10 allowed to cool to room temperature and then poured into ice. The pH was made slightly alkaline by the addition of saturated sodium bicarbonate (50 ml) before being extracted with ethyl acetate (3x100 ml). The organic phase was dried (MgSO₄), filtered and evaporated to afford the crude product. The crude product was further purified either by crystallization or flash chromatography to yield the title compound.

15 General procedure 5: Sulfonation of compounds of the general formula I (exemplified by compound 101) to the corresponding compounds of the general formula I (exemplified by compound 123) by treatment with various alkyl or aryl sulfonyl chlorides

To a cold (ice/water) solution of 4-(2-aminophenylamino)benzophenone (0.58 g, 2 mmol) in pyridine (10 ml) was added ethanesulfonyl chloride (0.25 ml, 2.7 mmol). The reaction mixture was warmed to room temperature. After stirring for 75 min, the reaction mixture was poured into ice water. The precipitate was filtered off, washed with
25 water, and diethyl ether to afford the title compound.

General procedure 6: Alkylation of compounds of the general formula I (exemplified by compound 101) to the corresponding compounds of the general formula I (exemplified by compound 134) by treatment with alkyl halogenide

30

A mixture of 4-(2-aminophenylamino)benzophenone (0.29 g, 1 mmol), methyl iodide (0.1 ml, 1.7 mmol) and potassium carbonate (0.28 g, 2 mmol) in *N,N*-dimethylformamide (5 ml) was stirred at room temperature for 4 days. The reaction mixture was evaporated *in vacuo*. The residue was extracted with ethyl acetate (25 ml),
5 filtered and evaporated to afford the crude product. The crude product was purified by flash chromatography using ethyl acetate/pentane 1:9 to give the title compound.

Preparation 1

10 4-(2-Nitrophenylamino)benzophenone (Compound 201)

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Crystallization from ethanol

15 Mp: 115-117 °C

¹H NMR (DMSO-d₆): δ 7.12 (m, 1H), 7.35 (d, 2H), 7.50-7.80 (m, 9H), 8.12 (dd, 1H), 9.37 (bs, 1H)

Preparation 2

20 4-(2-Nitrophenylamino)benzophenone (Compound 202)

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVb: 1-Fluoro-4-nitrobenzene

Mp: 208-210 °C

25 ¹H NMR (DMSO-d₆): δ 7.31 (d, 2H), 7.37 (d, 2H), 7.53-7.77 (m, 7H), 8.18 (d, 2H), 9.76 (s, 1H)

Preparation 3

4-(4-Methyl-2-nitrophenylamino)benzophenone (Compound 203)

30

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVa: 4-Fluoro-3-nitrotoluene

Purification: Chromatography using ethyl acetate/pentane 3:7 as eluant

Mp: 131-133 °C

5 ^1H NMR (DMSO- d_6): δ 2.34 (s, 3H), 7.25 (d, 2H), 7.47-7.75 (m, 9H), 7.93 (bs, 1H), 9.21 (bs, 1H)

Preparation 4

4-(4-Trifluoromethyl-2-nitrophenylamino)benzophenone (Compound 204)

10 General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVa: 2-Fluoro-5-trifluoromethyl-nitrobenzene

Mp: 139-141 °C

15 ^1H NMR (DMSO- d_6): δ 7.50-7.90 (m, 11H), 8.40 (bd, 1H), 9.82 (bs, 1H)

Preparation 5

4-(4-Benzoylphenylamino)-3-nitrobenzoic acid (Compound 205)

General procedure 1

Starting compound III: 4-Aminobenzophenone

20 Starting compound IVa: 4-Fluoro-3-nitrobenzoic acid

Mp: > 250 °C (potassium salt)

^1H NMR (DMSO- d_6): (potassium salt) δ 7.36 (d, 2H), 7.47 (d, 1H), 7.52-7.77 (m, 7H), 8.06 (dd, 1H), 8.53 (d, 1H), 9.44 (bs, 1H)

25

Preparation 6

2-(4-Benzoylphenylamino)-5-nitrobenzonitrile (Compound 206)

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVb: 2-Fluoro-5-nitrobenzonitrile

Mp: 208-210 °C

¹H NMR (DMSO-d₆): δ 7.45-7.85 (m, 10H), 8.31 (dd, 1H), 8.65 (d, 1H), 9.67 (bs, 1H)

5

Preparation 7

2-(4-Benzoylphenylamino)-5-nitrobenzoic acid (Compound 207)

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVb: 2-Fluoro-5-nitrobenzoic acid

10

Mp: 216-218 °C

¹H NMR (DMSO-d₆): δ 7.45-7.90 (m, 10H), 8.26 (dd, 1H), 8.74 (d, 1H), 10.65 (bs, 1H), 14.0 (bs, 1H)

Preparation 8

15 4-(2-Methyl-4-nitrophenylamino)benzophenone (Compound 208)

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVb: 2-Fluoro-5-nitrotoluene

Mp: 207-209 °C

20

¹H NMR (DMSO-d₆): δ 2.38 (s, 3H), 7.31 (d, 2H), 7.44 (d, 1H), 7.52-7.80 (m, 7H), 8.02 (dd, 1H), 8.14 (d, 1H), 8.67 (bs, 1H)

Preparation 9

2-Fluoro-4'-(2-nitrophenylamino)benzophenone (Compound 209)

25

General procedure 2

Starting compound III: 4-Amino-2'-fluorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using diethyl ether/pentane 1:2 as eluant

Mp: 131-132 °C

^1H NMR (CDCl_3): δ 6.94 (m, 1H), 7.17 (dd, 1H), 7.25-7.35 (m, 3H), 7.45-7.60 (m, 4H), 7.87 (m, 2H), 8.21 (dd, 1H), 9.51 (bs, 1H)

Preparation 10

5 4-Fluoro-4'-(2-nitrophenylamino)benzophenone (Compound 210)

General procedure 2

Starting compound III: 4-Amino-4'-fluorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Crystallization from acetone/water

10 Mp: 148-150 °C

^1H NMR (CDCl_3): δ 6.92 (m, 1H), 7.18 (m, 2H), 7.35 (d, 2H), 7.49 (m, 2H), 7.84 (m, 4H), 8.23 (dd, 1H), 9.52 (bs, 1H)

Preparation 11

15 4-Tert-butyl-4'-(2-nitrophenylamino)benzophenone (Compound 211)

General procedure 2

Starting compound III: 4-Amino-4'-tert-butylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Crystallization from methanol

20 Mp: 189-194 °C

^1H NMR (CDCl_3): δ 1.38 (s, 9H), 6.90 (m, 1H), 7.34 (d, 2H), 7.50 (m, 4H), 7.75 (d, 2H), 7.87 (d, 2H), 8.22 (dd, 1H), 9.53 (bs, 1H)

Preparation 12

25 3-Fluoro-4'-(2-nitrophenylamino)benzophenone (Compound 212)

General procedure 2

Starting compound III: 4-Amino-3'-fluorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Crystallization from methanol

^1H NMR (CDCl_3): δ 6.94 (m, 1H), 7.25-7.65 (m, 8H), 7.86 (d, 2H), 8.23 (dd, 1H), 9.52 (s, 1H)

Preparation 13

5 2-Chloro-4'-(2-nitrophenylamino)benzophenone (Compound 213)

General procedure 2

Starting compound III: 4-Amino-2'-chlorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using diethyl ether/pentane 3:7 as eluant

10 ^1H NMR (CDCl_3): δ 6.95 (m, 1H), 7.25-7.57 (m, 8H), 7.83 (d, 2H), 8.22 (dd, 1H), 9.49 (bs, 1H)

Preparation 14

15 3-Chloro-4'-(2-nitrophenylamino)benzophenone (Compound 214)

General procedure 2

Starting compound III: 4-Amino-3'-chlorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

^1H NMR (CDCl_3): δ 6.94 (m, 1H), 7.32-7.62 (m, 6H), 7.66 (d, 1H), 7.76 (bs, 1H), 7.86 (d, 2H), 8.23 (dd, 1H), 9.52 (s, 1H)

20

Preparation 15

25 2-Methoxy-4'-(2-nitrophenylamino)benzophenone (Compound 215)

General procedure 2

Starting compound III: 4-Amino-2'-methoxybenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using diethyl ether/pentane 1:2 as eluant

^1H NMR (CDCl_3): δ 3.76 (s, 3H), 6.94 (m, 1H), 7.05 (m, 2H), 7.27 (d, 2H), 7.36 (dd, 1H), 7.50 (m, 3H), 7.84 (d, 2H), 8.21 (dd, 1H), 9.50 (s, 1H)

Preparation 163-Dimethylamino-4'-(2-nitrophenylamino)benzophenone (Compound 216)

General procedure 2

Starting compound III: 4-Amino-3'-(dimethylamino)benzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^1H NMR (CDCl_3): δ 3.00 (s, 6H), 6.92 (m, 2H), 7.04 (dd, 1H), 7.15 (m, 1H),
7.28 (m, 3H), 7.50 (m, 2H), 7.89 (d, 2H), 8.21 (dd, 1H), 9.52 (bs, 1H)

10

Preparation 174-Chloro-4'-(2-nitrophenylamino)benzophenone (Compound 217)

General procedure 2

Starting compound III: 4-Amino-4'-chlorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

15 Purification: Crystallization from ethyl acetate/pentane 1:2

Mp: 157-158 °C

^1H NMR (CDCl_3): δ 6.93 (m, 1H), 7.35 (d, 2H), 7.50 (m, 4H), 7.75 (d, 2H),
7.84 (d, 2H), 8.23 (dd, 1H), 9.52 (s, 1H)

20

Preparation 183-Methyl-4'-(2-nitrophenylamino)benzophenone (Compound 218)

General procedure 2

Starting compound III: 4-Amino-3'-methylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

Mp: 86-87 °C

^1H NMR (CDCl_3): δ 2.43 (s, 3H), 6.92 (m, 1H), 7.30-7.65 (m, 8H), 7.87 (d,
2H), 8.22 (dd, 1H), 9.52 (s, 1H)

Preparation 193-Nitro-4-(4-nitrophenylamino)benzophenone (Compound 219)

General procedure 1

Starting compound III: 4-Amino-3-nitrobenzophenone

5 Starting compound IVa: 1-Fluoro-4-nitrobenzene

Purification: Crystallization from n-propanol

Mp: 199-201 °C

 ^1H NMR (DMSO- d_6): δ 7.50-7.80 (m, 8H), 7.99 (dd, 1H), 8.25 (d, 2H), 8.44 (d, 1H), 9.98 (s, 1H)

10

Preparation 204-(2-Nitrophenylamino)-4'-pentylbenzophenone (Compound 220)

General procedure 2

Starting compound III: 4-Amino-4'-pentylbenzophenone

15 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Crystallization from ethyl acetate

Mp: 93-95 °C

 ^1H NMR (CDCl₃): δ 0.92 (t, 3H), 1.40 (m, 4H), 1.73 (m, 2H), 3.01 (t, 2H), 6.92 (m, 1H), 7.34 (m, 4H), 7.47 (m, 2H), 7.73 (d, 2H), 7.84 (d, 2H), 8.23 (dd, 1H), 9.52 (s, 1H)

20

Preparation 214-Chloro-2-isopropylthio-4'-(2-nitrophenylamino)benzophenone (Compound 221)

General procedure 2

25 Starting compound III: 4'-Amino-4-chloro-2-(isopropylthio)benzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

 ^1H NMR (CDCl₃): δ 1.25 (d, 6H), 3.40 (m, 1H), 6.94 (m, 1H), 7.27 (m, 4H), 7.50 (m, 3H), 7.79 (d, 2H), 8.21 (dd, 1H), 9.49 (bs, 1H)

Preparation 224-Trifluoromethyl-4'-(2-nitrophenylamino)benzophenone (Compound 222)

General procedure 2

Starting compound III: 4-Amino-4'-trifluoromethylbenzophenone

5

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

Mp: 122-123 °C

¹H NMR (CDCl₃): δ 6.96 (m, 1H), 7.36 (d, 2H), 7.50 (m, 2H), 7.77 (d, 2H),
7.87 (m, 4H), 8.23 (dd, 1H), 9.52 (s, 1H)

10

Preparation 233,4,5-Trimethoxy-4'-(2-nitrophenylamino)benzophenone (Compound 223)

General procedure 2

Starting compound III: 4'-Amino-3,4,5-trimethoxybenzophenone

15

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Trituration from ethyl acetate/pentane 1:2

Mp: sublimate 180-191 °C

¹³C NMR (CDCl₃): δ 194.4, 152.9, 143.3, 142.0, 140.4, 135.7, 135.0, 133.4,
132.8, 132.0, 126.8, 120.9, 119.5, 117.2, 107.6, 61.0, 56.4

20

Preparation 244-(N-Methyl-2-nitrophenylamino)benzophenone (Compound 224)

General procedure 6, but using 5 mmol methyl iodide

Starting compound : 201

25

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

¹H NMR (DMSO-d₆): δ 8.09 (m, 1H), 7.87 (m, 1H), 7.68-7.57 (m, 7H), 7.52
(m, 2H), 6.65 (m, 2H), 3.34 (s, 3H)

Preparation 252-Methyl-4'-(2-nitrophenylamino)benzophenone (Compound 225)

General procedure 2

Starting compound III: 4-Amino-2'-methylbenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

Mp: 87-90 °C

¹³C NMR (CDCl₃): δ 197.0, 144.0, 140.2, 138.7, 136.5, 135.6, 135.2, 133.3,
132.1, 131.0, 130.1, 128.1, 126.8, 125.3, 120.8, 119.6, 117.4, 19.9

10

Preparation 262,4-Dichloro-4'-(2-nitrophenylamino)benzophenone (Compound 226)

General procedure 2

Starting compound III: 4'-Amino-2,4-dichlorobenzophenone

15 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

¹³C NMR (CDCl₃): δ 192.6, 144.9, 139.6, 137.1, 136.5, 135.6, 132.3,
132.1, 131.6, 130.0, 127.2, 126.8, 120.4, 120.1, 117.7

20

Preparation 273,4-Ethylenedioxy-4'-(2-nitrophenylamino)benzophenone (Compound 227)

General procedure 2

Starting compound III: 4'-Amino-3,4-ethylenedioxybenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

Mp: 145-147 °C

¹³C NMR (CDCl₃): δ 193.9, 147.6, 143.2, 142.9, 140.8, 135.7, 134.8, 133.9,
131.9, 131.1, 126.8, 124.2, 121.2, 119.6, 119.2, 117.1, 117.0, 64.7, 64.2

Preparation 282,4'-Dichloro-4-(2-nitrophenylamino)benzophenone (Compound 228)

General procedure 2

Starting compound III: 4-Amino-2,4'-dichlorobenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

Mp: 140-142 °C

^{13}C NMR (CDCl_3): δ 193.3, 142.5, 140.2, 140.2, 135.8, 135.2, 135.1, 133.6,
133.2, 131.4, 131.1, 129.0, 126.9, 123.0, 120.0, 119.7, 117.0

10

Preparation 294-(2-Nitrophenylamino)-4'-(1-methylbutyloxy)benzophenone (Compound 229)

General procedure 2

Starting compound III: 4-Amino-4'-(1-methylbutyloxy)benzophenone

15 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 194.1, 162.1, 142.7, 140.9, 135.7, 134.7, 134.3, 132.4,
131.8, 129.8, 126.8, 121.3, 119.1, 117.0, 115.0, 73.9, 38.5, 19.7, 18.7, 14.0

20

Preparation 302,3-Dimethoxy-4'-(2-nitrophenylamino)benzophenone (Compound 230)

General procedure 2

Starting compound III: 4'-Amino-2,3-dimethoxybenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Chromatography using diethyl ether/pentane 1:1 as eluant

^{13}C NMR (CDCl_3): δ 194.6, 152.8, 146.7, 144.0, 140.2, 135.6, 135.1, 134.2,
133.1, 132.0, 126.8, 124.2, 120.7, 120.3, 119.5, 117.4, 114.2, 61.8, 56.0

Preparation 313-Butoxy-4'-(2-nitrophenylamino)benzophenone (Compound 231)

General procedure 2

Starting compound III: 4-Amino-3'-butoxybenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using diethyl ether/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 195.1, 159.2, 143.4, 140.5, 139.0, 135.7, 135.0, 133.3, 132.1, 129.2, 126.8, 122.3, 121.0, 119.4, 119.0, 117.2, 115.0, 68.0, 31.3, 19.2, 13.9

10

Preparation 324-(2-Nitrophenylamino)-3'-(trifluoromethyl)benzophenone (Compound 232)

General procedure 2

Starting compound III: 4-Amino-3'-(trifluoromethyl)benzophenone

15 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant followed by trituration from diethyl ether

^{13}C NMR (CDCl_3): δ 193.7, 144.1, 140.0, 138.6, 135.7, 135.4, 132.9, 132.2, 132.1, 131.0, 129.0, 128.7, 126.9, 126.5, 123.7, 120.8, 119.8, 117.4

20

Preparation 333,5-Dichloro-4'-(2-nitrophenylamino)benzophenone (Compound 233)

General procedure 2

Starting compound III: 4'-Amino-3,5-dichlorobenzophenone

25 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using diethyl ether/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 192.2, 144.4, 140.5, 139.8, 135.6, 135.5, 135.3, 132.2, 131.9, 131.6, 127.9, 126.9, 120.6, 119.9, 117.5

Preparation 344-Benzyloxy-4'-(2-nitrophenylamino)benzophenone (Compound 234)

General procedure 2

Starting compound III: 4-Amino-4'-benzyloxybenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 193.9, 162.1, 142.6, 140.6, 136.0, 135.4, 134.6, 133.8, 132.1, 131.6, 130.3, 128.5, 128.0, 127.3, 126.6, 121.0, 119.0, 116.8, 114.3, 70.0

10

Preparation 354-Ethoxy-4'-(2-nitrophenylamino)benzophenone (Compound 235)

General procedure 2

Starting compound III: 4-Amino-4'-ethoxybenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

15 Purification: Trituration from diethyl ether/pentane 1:2

^{13}C NMR (CDCl_3): δ 194.1, 162.6, 142.8, 140.8, 135.7, 134.8, 134.2, 132.4, 131.8, 130.0, 126.8, 121.3, 119.1, 117.0, 114.1, 63.8, 14.7

Preparation 36

20 4-(2-Chloro-4-nitrophenylamino)benzophenone (Compound 236)

General procedure 1

Starting compound III: 4-Aminobenzophenone

Starting compound IVb: 1-Chloro-2-fluoro-5-nitrobenzene

Purification: Trituration from ethanol

25 Mp: 214-218 °C

^1H NMR ($\text{DMSO}-d_6$): δ 9.08 (bs, 1H), 8.33 (d, 1H), 8.11 (dd, 1H), 7.83-7.63 (m, 5H), 7.57 (m, 2H), 7.50 (d, 1H), 7.43 (d, 2H)

Preparation 373-Methoxy-4-methyl-4'-(2-nitrophenylamino)benzophenone (Compound 237)

General procedure 2

Starting compound III: 4'-Amino-3-methoxy-4-methylbenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Trituration from methanol

^{13}C NMR (CDCl_3): δ 195.2, 157.9, 143.2, 140.6, 136.5, 135.7, 134.9, 133.7, 132.3, 132.0, 130.0, 126.8, 123.0, 121.1, 119.3, 117.1, 110.5, 55.5, 16.5

10

Preparation 382-Chloro-4-(2-nitrophenylamino)benzophenone (Compound 238)

General procedure 2

Starting compound III: 4-Amino-3-chlorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

15 Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant followed by crystallization from methanol

^{13}C NMR (CDCl_3): δ 194.5, 142.2, 140.5, 136.8, 135.8, 134.9, 134.2, 133.6, 133.2, 131.1, 130.1, 128.6, 126.9, 123.2, 120.1, 119.5, 116.9

20

Preparation 394-Methoxy-4'-(2-nitrophenylamino)benzophenone (Compound 239)

General procedure 2

Starting compound III: 4-Amino-4'-methoxybenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Crystallization from ethyl acetate

^{13}C NMR (CDCl_3): δ 194.1, 163.2, 142.8, 140.8, 135.7, 134.8, 134.1, 132.4, 131.8, 130.3, 126.8, 121.3, 119.2, 117.0, 113.6, 55.5

Preparation 403-Methyl-4-(2-nitrophenylamino)benzophenone (Compound 240)

General procedure 2

Starting compound III: 4-Amino-3-methylbenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Crystallization from ethanol

^{13}C NMR (CDCl_3): δ 5.6, 141.7, 141.4, 137.8, 135.7, 134.3, 134.1, 133.4, 132.3, 131.7, 129.9, 129.4, 128.3, 126.8, 121.9, 118.7, 116.8, 18.1

10

Preparation 414-(2-Nitrophenylamino)-2'-phenylbenzophenone (Compound 241)

General procedure 2

Starting compound III: 4-Amino-2'-phenylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

15 Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 197.2, 143.4, 141.0, 140.4, 140.2, 138.9, 135.5, 135.0, 133.3, 131.8, 130.4, 130.0, 129.1, 128.7, 128.3, 127.4, 127.2, 126.8, 120.7, 119.4, 117.2

20

Preparation 424-(2-Nitrophenylamino)-3'-phenylbenzophenone (Compound 242)

General procedure 2

Starting compound III: 4-Amino-3'-phenylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Crystallization from a mixture of chloroform/methanol

Mp: 142-145 °C

^{13}C NMR (CDCl_3): δ 195.2, 143.5, 141.4, 140.4, 140.2, 138.4, 135.6, 135.0, 133.1, 132.2, 130.9, 128.9, 128.8, 128.6, 128.4, 127.8, 127.2, 126.8, 120.9, 119.5, 117.2

Preparation 432-Chloro-2'-methyl-4-(2-nitrophenylamino)benzophenone (Compound 243)

General procedure 2

Starting compound III: 4-Amino-2-chloro-2'-methylbenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 followed by methylene chloride/pentane 2:1 as eluant

^{13}C NMR (CDCl_3): δ 196.4, 142.7, 140.1, 139.0, 137.6, 135.8, 135.1, 134.7, 134.0, 132.2, 131.8, 131.7, 130.6, 126.9, 125.6, 123.0, 119.8, 119.7, 117.1, 20.9

10

Preparation 443-Cyano-4'-(2-nitrophenylamino)benzophenone (Compound 244)

General procedure 2

Starting compound III: 4-Amino-3'-cyanobenzophenone

15 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:3 as eluant

^{13}C NMR (CDCl_3): δ 192.8, 144.4, 139.8, 138.9, 135.7, 135.5, 135.2, 133.6, 133.2, 132.2, 131.6, 129.5, 126.9, 120.7, 120.0, 118.0, 117.5, 112.8

20

Preparation 454-(2-Nitrophenylamino)-4'-phenylbenzophenone (Compound 245)

General procedure 2

Starting compound III: 4-Amino-4'-phenylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Trituration from diethyl ether followed by chromatography using ethyl acetate/pentane 1:8 as eluant

^{13}C NMR ($\text{DMSO}-d_6$): δ 193.7, 145.4, 143.6, 139.0, 138.0, 137.6, 136.4, 135.4, 131.7, 130.5, 130.0, 129.0, 128.2, 126.9, 126.6, 126.1, 121.2, 120.4, 118.6

Preparation 462-Methyl-4'-(4-nitrophenylamino)benzophenone (Compound 246)

General procedure 2

Starting compound III: 4-Amino-2'-methylbenzophenone

5 Starting compound IVb: 1-Fluoro-4-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 followed by 1:2 as eluant

^{13}C NMR (CDCl_3): δ 197.3, 147.8, 145.2, 141.2, 138.9, 136.3, 132.4, 132.0, 131.0, 130.1, 128.0, 126.0, 125.3, 118.0, 116.2, 19.8

10

Preparation 472-Hydroxy-4'-(2-nitrophenylamino)benzophenone (Compound 247)

To a cooled (-78°C) solution of 2-Methoxy-4'-(2-nitrophenylamino)-benzophenone (Compound 215, 0.35 g, 1 mmol) in methylene chloride (10 ml), under
15 argon, was added boron tribromide (0.1 ml, 1 mmol) under stirring. The reaction mixture was allowed to come to room temperature. After stirring for 3 h, the reaction mixture was poured into saturated sodium bicarbonate (50 ml) before being extracted with ethyl acetate (2x50ml). The organic phase was dried (MgSO_4), filtered and evaporated to afford the title compound.

20

Mp: 189-193 $^\circ\text{C}$

^{13}C NMR (CDCl_3): δ 199.8, 163.1, 143.1, 140.5, 136.2, 135.7, 135.0, 133.6, 133.2, 131.4, 126.9, 121.2, 119.4, 119.2, 118.7, 118.5, 117.1

Preparation 48

25 2-Ethyl-4'-(2-nitrophenylamino)benzophenone (Compound 248)

General procedure 2

Starting compound III: 4-Amino-2'-ethylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using diethyl ether/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 197.1, 144.1, 142.8, 140.1, 138.5, 135.6, 135.2, 133.4, 132.2, 130.2, 129.4, 128.0, 126.8, 125.2, 120.7, 119.6, 117.4, 26.4, 15.9

Preparation 49

5 4-(2-Nitrophenylamino)-2'-(phenoxymethyl)benzophenone (Compound 249)

General procedure 2

Starting compound III: 4-Amino-2'-(phenoxymethyl)benzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

10 ^{13}C NMR (CDCl_3): δ 196.1, 158.4, 144.0, 140.2, 137.7, 136.7, 135.6, 135.2, 133.1, 132.2, 130.6, 129.4, 128.7, 128.6, 127.3, 126.8, 121.0, 120.7, 119.6, 117.4, 114.7, 67.5

Preparation 50

15 2-Bromo-4'-(2-nitrophenylamino)benzophenone (Compound 250)

General procedure 2

Starting compound III: 4-Amino-2'-bromobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

20 ^{13}C -NMR (CDCl_3): δ 194.2, 144.6, 140.8, 139.8, 135.6, 135.5, 133.2, 132.3, 131.6, 131.1, 128.9, 127.3, 126.8, 120.5, 119.9, 119.5, 117.6

Preparation 51

25 2,3,5,6-Tetramethyl-4'-(2-nitrophenylamino)benzophenone (Compound 251)

General procedure 2

Starting compound III: 4'-Amino-2,3,5,6-tetramethylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using methylene chloride/pentane 1:2 followed by 1:1 as eluant

^{13}C NMR (CDCl_3): δ 200.0, 144.3, 140.0, 139.9, 135.6, 135.3, 134.2, 133.2, 131.8, 131.5, 129.7, 126.8, 120.8, 119.7, 117.5, 19.5, 16.3

Preparation 52

5 3-Methoxy-2'-methyl-4-(2-nitrophenylamino)benzophenone (Compound 252)

General procedure 2

Starting compound III: 4-Amino-3-methoxy-2'-methylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using methylene chloride/pentane 2:3 as eluant

10 ^{13}C NMR (CDCl_3): δ 197.1, 150.2, 139.2, 138.9, 136.3, 136.1, 135.3, 134.3, 132.5, 130.9, 130.0, 128.0, 126.8, 125.2, 119.7, 117.8, 116.6, 111.2, 56.1, 19.8

Preparation 53

2',3-Dimethyl-4-(2-nitrophenylamino)benzophenone (Compound 253)

15 General procedure 2

Starting compound III: 4-Amino-2',3-dimethylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

20 ^{13}C NMR (CDCl_3): δ 197.5, 142.4, 141.0, 138.8, 136.5, 135.7, 134.6, 134.0, 133.3, 131.3, 131.0, 130.1, 129.5, 128.2, 126.8, 125.2, 121.3, 119.0, 117.0, 19.9, 18.0

Preparation 54

2-Allyloxy-4'-(2-nitrophenylamino)benzophenone (Compound 254)

25 General procedure 2

Starting compound III: 2-Allyloxy-4'-aminobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

^{13}C NMR (CDCl_3): δ 195.0, 156.2, 143.5, 140.6, 135.6, 135.0, 134.0, 132.5,

Preparation 552-Methoxy-2'-methyl-4-(2-nitrophenylamino)benzophenone (Compound 255)

General procedure 2

Starting compound III: 4-Amino-2-methoxy-2'-methylbenzophenone

5 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 196.9, 160.2, 144.0, 140.8, 139.9, 137.4, 135.6, 134.8, 132.9, 131.1, 130.5, 129.3, 126.8, 125.4, 125.2, 119.2, 117.3, 113.5, 105.6, 55.9, 20.5

10

Preparation 562-Tert-butoxy-4'-(2-nitrophenylamino)benzophenone (Compound 256)

General procedure 2

Starting compound III: 4-Amino-2'-tert-butoxybenzophenone

15 Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:10 as eluant

^{13}C NMR (CDCl_3): δ 196.1, 153.6, 143.4, 140.6, 135.6, 134.9, 134.8, 134.2, 131.8, 131.3, 129.7, 126.8, 123.0, 122.8, 120.9, 119.2, 117.2, 80.3, 28.8

20

Preparation 572-Chloro-4-(2-nitrophenylamino)-2'-(trifluoromethyl)benzophenone (Compound 257)

General procedure 2

Starting compound III: 4-Amino-2-chloro-2'-(trifluoromethyl)benzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

25 Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

Mp: 125-127 °C

^{13}C NMR (CDCl_3): δ 193.0, 144.4, 139.2, 135.8, 135.7, 134.3, 131.6, 131.1, 130.6, 128.8, 128.3, 127.0, 126.9, 123.6, 122.5, 120.5, 118.5, 117.8

Preparation 583-Allyl-2-hydroxy-4'-(2-nitrophenylamino)benzophenone (Compound 258)

2-Allyloxy-4'-(2-nitrophenylamino)benzophenone (Compound 254, 1.57 g, 4.2 mmol) was heated to 220 °C under argon. After 4 h the reaction mixture was cooled to room temperature. The crude product was further purified by chromatography using ethyl acetate/pentane 1:8 as eluant to afford the title compound.

^{13}C NMR (CDCl_3): δ 200.1, 161.1, 143.0, 140.6, 136.3, 136.1, 135.7, 135.0, 133.8, 131.4, 129.5, 126.9, 121.2, 119.4, 118.7, 118.2, 117.1, 116.1, 33.6

10

Preparation 592'-Chloro-4-methoxy-2,6-dimethyl-4'-(2-nitrophenylamino)benzophenone (Compound 259)

General procedure 2

Starting compound III: 4'-Amino-2'-chloro-4-methoxy-2,6-dimethylbenzophenone

15

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 followed by 1:4 as eluant

^{13}C NMR (CDCl_3): δ 197.2, 160.1, 143.7, 139.5, 137.2, 135.7, 135.6, 135.2, 133.6, 133.0, 126.9, 123.0, 120.2, 118.9, 117.6, 113.4, 55.2, 20.2

20

Preparation 602-Chloro-2'-methyl-4-(2-nitro-4-methylphenylamino)benzophenone (Compound 260)

General procedure 2

Starting compound III: 4-Amino-2-chloro-2'-methylbenzophenone

25

Starting compound IVa: 1-Fluoro-4-methyl-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 followed by 1:4 as eluant

^{13}C NMR (CDCl_3): δ 196.4, 143.3, 138.8, 137.8, 137.5, 136.9, 135.4, 134.1, 134.0, 132.3, 131.7, 131.6, 130.5, 130.1, 126.3, 125.5, 122.2, 118.8, 117.6, 20.8, 20.3

5

Preparation 612-Chloro-2'-methyl-4-(4-nitrophenylamino)benzophenone (Compound 261)

General procedure 2

Starting compound III: 4-Amino-2-chloro-2'-methylbenzophenone

Starting compound IVb: 1-Fluoro-4-nitrobenzene

10

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^{13}C NMR ($\text{DMSO}-d_6$): δ 148.4, 144.7, 144.7, 139.9, 138.0, 137.4, 132.7, 132.7, 131.6, 131.5, 131.2, 129.8, 126.0, 125.9, 119.3, 116.5, 116.0, 20.2

Preparation 6215 2-Chloro-2'-methoxy-4-(2-nitrophenylamino)benzophenone (Compound 262)

General procedure 2

Starting compound III: 4-Amino-2-chloro-2'-methoxybenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using methylene chloride/pentane 3:1 as eluant

20

Mp: 111-114 °C

^{13}C NMR (CDCl_3): δ EO 193.6, 158.8, 142.1, 140.5, 135.9, 135.8, 134.9, 133.9, 133.5, 131.7, 131.1, 128.3, 126.8, 123.0, 120.8, 119.9, 119.5, 117.0, 111.8, 55.8

25

Preparation 632'-Chloro-2,4,5-trifluoro-4'-(2-nitrophenylamino)benzophenone (Compound 263)

General procedure 2

Starting compound III: 4'-Amino-2-chloro-2,4,5-trifluorobenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

30

Purification: Chromatography using ethyl acetate/pentane 1:8 as eluant

^{13}C NMR (CDCl_3): δ 185.1, 155.2, 147.9, 147.1, 144.8, 138.9, 136.1, 135.7, 135.4, 133.6, 131.4, 126.9, 122.1, 120.7, 119.9, 119.4, 118.6, 118.0, 111.6

Preparation 64

5 2-Chloro-2',6'-dimethyl-4-(2-nitrophenylamino)benzophenone (Compound 264)

General procedure 2

Starting compound III: 4-Amino-2-chloro-2',6'-dimethylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

10 ^{13}C NMR (CDCl_3): δ 197.3, 144.1, 140.3, 139.2, 135.8, 135.7, 135.6, 134.6, 134.0, 131.6, 129.2, 127.9, 126.9, 123.0, 120.4, 118.6, 117.8, 19.6

Preparation 65

2-Chloro-4'-fluoro-2'-methyl-4-(2-nitrophenylamino)benzophenone (Compound 265)

15 General procedure 2

Starting compound III: 4-Amino-2-chloro-4'-fluoro-2'-methylbenzophenone

Starting compound IVa: 1-Fluoro-2-nitrobenzene

Purification: Chromatography using ethyl acetate/pentane 1:10 as eluant

20 ^{13}C NMR (CDCl_3): δ 195.0, 162.4, 142.9, 142.8, 140.1, 135.8, 135.2, 134.7, 133.8, 133.8, 133.4, 131.9, 126.9, 123.0, 119.8, 119.7, 118.7, 117.1, 112.6, 21.2

Preparation 66

4-(5-Hydroxy-2-nitrophenylamino)benzophenone (Compound 266)

General procedure 1.

25 Starting compound III: 4-Aminobenzophenone

Starting compound IVa: 3-Fluoro-4-nitrophenol

Purification: Trituration from ethanol

Mp: 235-238 °C

^1H NMR ($\text{DMSO}-d_6$): δ 10.94 (bs, 1H), 9.64 (s, 1H), 8.10 (d, 1H), 7.84-7.63

Example 14-(2-Aminophenylamino)benzophenone (Compound 101)

General procedure 3

Starting compound II: 201

5 Mp: 115-116 °C

¹H NMR (CDCl₃): δ 3.67 (bs, 2H), 5.74 (bs, 1H), 6.69 (d, 2H), 6.75-6.85 (m, 2H), 7.05-7.16 (m, 2H), 7.40-7.60 (m, 3H), 7.70-7.80 (m, 4H)

Example 210 4-(4-Aminophenylamino)benzophenone (Compound 102)

General procedure 3

Starting compound II: 202

Mp: 152-154 °C

15 ¹H NMR (DMSO-d₆): δ 4.98 (bs, 2H), 6.58 (d, 2H), 6.79 (d, 2H), 6.90 (d, 2H), 7.50-7.65 (m, 7H), 8.41 (bs, 1H)

Example 34-(2-Amino-4-methylphenylamino)benzophenone (Compound 103)

General procedure 3

20 Starting compound II: 203

Mp: 153-155 °C

¹H NMR (DMSO-d₆): δ 2.19 (s, 3H), 4.78 (bs, 2H), 6.40 (dd, 1H), 6.60 (bs, 1H), 6.67 (d, 2H), 6.90 (d, 1H), 7.45-7.65 (m, 7H), 7.98 (bs, 1H)

25

Example 44-(2-Amino-4-trifluoromethylphenylamino)benzophenone (Compound 104)

General procedure 3

Starting compound II: 204

Mp: 184-186 °C

^1H NMR (DMSO- d_6): δ 5.37 (bs, 2H), 6.88 (m, 3H), 7.09 (bd, 1H), 7.27 (d, 1H), 7.50-7.70 (m, 7H), 8.20 (bs, 1H)

Example 5

5 3-Amino-4-(4-benzoylphenylamino)benzoic acid (Compound 105)

General procedure 3

Starting compound II: 205

Purification: Crystallization from a mixture of water and acetic acid

Mp: 205-207 °C

10 ^1H NMR (DMSO- d_6): δ 5.17 (b, 2H), 6.92 (d, 2H), 7.19 (m, 2H), 7.43 (bs, 1H),
7.50-7.65 (m, 8H), 8.23 (bs, 1H)

Example 6

15 5-Amino-2-(4-benzoylphenylamino)benzonitrile (Compound 106)

General procedure 3

Starting compound II: 206

Mp: 168-170 °C

^1H NMR (DMSO- d_6): δ 5.56 (bs, 2H), 6.75 (d, 2H), 6.91 (m, 2H), 7.14 (m, 1H), 7.50-7.70 (m, 7H), 8.63 (bs, 1H)

20

Example 7

25 5-Amino-2-(4-benzoylphenylamino)benzoic acid (Compound 107)

General procedure 3

Starting compound II: 207

Purification: Crystallization from ethanol

Mp: 222-223 °C

^1H NMR (DMSO- d_6): δ 6.81 (dd, 1H), 6.97 (d, 2H), 7.18 (m, 2H), 7.50-7.70 (m, 7H), 7.60 (b, 3H), 8.86 (bs, 1H)

Example 84-(4-Amino-2-methylphenylamino)benzophenone (Compound 108)

General procedure 3

Starting compound II: 208

5 Mp: 140-142 °C

¹H NMR (DMSO-d₆): δ 2.03 (s, 3H), 4.99 (bs, 2H), 6.43 (dd, 1H), 6.50 (m, 1H), 6.56 (d, 2H), 6.84 (d, 1H), 7.45-7.65 (m, 7H), 8.07 (s, 1H)

Example 910 4-(2-Aminophenylamino)-2'-fluorobenzophenone (Compound 109)

General procedure 4

Starting compound II: 209

Mp: 153-154 °C

15 ¹H NMR (CDCl₃): δ 3.83 (bs, 2H), 5.74 (bs, 1H), 6.68 (d, 2H), 6.78 (m, 2H), 7.05-7.25 (m, 4H), 7.45 (m, 2H), 7.72 (d, 2H)

Example 104-(2-Aminophenylamino)-4'-fluorobenzophenone (Compound 110)

General procedure 4

20 Starting compound II: 210

Purification: Trituration with diethyl ether

Mp: 135-136 °C

25 ¹H NMR (CDCl₃): δ 3.79 (bs, 2H), 5.73 (bs, 1H), 6.69 (d, 2H), 6.75-6.85 (m, 2H), 7.07-7.17 (m, 4H), 7.65-7.80 (m, 4H)

Example 114-(2-Aminophenylamino)-4'-tert-butylbenzophenone (Compound 111)

General procedure 4

Starting compound II: 211

Mp: 183-185°C

^1H NMR (CDCl_3): δ 1.34 (s, 9H), 3.81 (s, 2H), 5.80 (bs, 1H), 6.68 (d, 2H), 6.77 (m, 2H), 7.05-7.15 (m, 2H), 7.45 (d, 2H), 7.66 (d, 2H), 7.74 (d, 2H)

5

Example 12

4-(2-Aminophenylamino)-3'-fluorobenzophenone (Compound 112)

General procedure 4

Starting compound II: 212

Purification: Trituration with diethyl ether

10

Mp: 115-116 °C

^1H NMR (CDCl_3): δ 3.80 (bs, 2H), 5.73 (bs, 1H), 6.70 (d, 2H), 6.75-6.85 (m, 2H), 7.07-7.27 (m, 3H), 7.35-7.52 (m, 3H), 7.70 (d, 2H)

Example 13

15 4-(2-Aminophenylamino)-2'-chlorobenzophenone (Compound 113)

General procedure 4

Starting compound II: 213

Mp: 182-183 °C

20

^1H NMR (CDCl_3): δ 3.77 (bs, 2H), 5.75 (bs, 1H), 6.66 (d, 2H), 6.72-6.85 (m, 2H), 7.07-7.15 (m, 2H), 7.30-7.45 (m, 4H), 7.66 (d, 2H)

Example 14

4-(2-Aminophenylamino)-3'-chlorobenzophenone (Compound 114)

General procedure 4

25

Starting compound II: 214

Purification: Trituration with diethyl ether

Mp: 107-108 °C (sublimates)

^1H NMR (CDCl_3): δ 3.00 (bs, 2H), 5.73 (bs, 1H), 6.70 (d, 2H), 6.75-6.85 (m, 2H), 7.07-7.17 (m, 2H), 7.37 (t, 1H), 7.50 (m, 1H), 7.58 (m, 1H), 7.70 (m, 3H)

Example 154-(2-Aminophenylamino)-2'-methoxybenzophenone (Compound 115)

General procedure 4

Starting compound II: 215

5 ^1H NMR (CDCl_3): δ 3.72 (s, 3H), 3.77 (bs, 2H), 5.57 (bs, 1H), 6.63 (d, 2H),
6.77 (m, 2H), 6.95-7.15 (m, 4H), 7.26 (m, 1H), 7.40 (m, 1H), 7.68 (d, 2H)

Example 164-(2-Aminophenylamino)-3'-(dimethylamino)benzophenone (Compound 116)

10 General procedure 4

Starting compound II: 216

^1H NMR (CDCl_3): δ 2.96 (s, 6H), 3.79 (bs, 2H), 5.69 (bs, 1H), 6.68 (d, 2H),
6.75-6.90 (m, 3H), 7.00 (bd, 1H), 7.05-7.16 (m, 3H), 7.26 (d, 1H), 7.76 (d, 2H)

15

Example 174-(2-Aminophenylamino)-4'-chlorobenzophenone (Compound 117)

General procedure 4

Starting compound II: 217

Purification: Trituration with diethyl ether

20

Mp: 164-167 °C

^1H NMR (CDCl_3): δ 3.80 (bs, 2H), 5.60 (bs, 1H), 6.70 (d, 2H), 6.75-6.85 (m,
2H), 7.07-7.17 (m, 2H), 7.41 (d, 2H), 7.65-7.75 (m, 4H)

Example 1825 4-(2-Aminophenylamino)-3'-methylbenzophenone (Compound 118)

General procedure 4

Starting compound II: 218

Purification: Trituration with diethyl ether

Mp: 119-120 °C

^1H NMR (CDCl_3): δ 2.39 (s, 3H), 3.80 (bs, 1H), 5.75 (bs, 1H), 6.70 (d, 2H), 6.75-6.85 (m, 2H), 7.05-7.17 (m, 2H), 7.31 (m, 2H), 7.47-7.55 (m, 2H), 7.72 (d, 2H)

5

Example 193-Amino-4-(4-aminophenylamino)benzophenone (Compound 119)

General procedure 3

Starting compound II: 219

Mp: 151-153 °C

10

^1H NMR ($\text{DMSO}-d_6$): δ 4.92 (s, 2H), 4.96 (bs, 2H), 6.58 (d, 2H), 6.67 (d, 1H), 6.89 (m, 3H), 7.06 (s, 1H), 7.16 (d, 1H), 7.45-7.65 (m, 5H)

Example 204-(2-Aminophenylamino)-4'-n-pentylbenzophenone (Compound 120)

15

General procedure 4

Starting compound II: 220

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

20

^1H NMR (CDCl_3): δ 0.91 (t, 3H), 1.30-1.50 (m, 4H), 1.70 (m, 2H), 2.99 (t, 2H), 3.80 (bs, 2H), 5.70 (bs, 1H), 6.70 (d, 2H), 6.75-6.85 (m, 2H), 7.05-7.20 (m, 2H), 7.30 (d, 2H), 7.66 (d, 2H), 7.71 (d, 2H)

Example 214'-(2-Aminophenylamino)-4-chloro-2-(isopropylthio)benzophenone (Compound 121)

General procedure 4

25

Starting compound II: 221

Purification: Chromatography using ethyl acetate/pentane 1:3 as eluant

^1H NMR (CDCl_3): δ 1.21 (d, 6H), 3.38 (m, 1H), 3.77 (bs, 2H), 5.80 (bs, 1H), 6.65 (d, 2H), 6.72-6.85 (m, 2H), 7.05-7.15 (m, 2H), 7.20 (m, 2H), 7.45 (bs, 1H), 7.63 (d, 2H)

Example 224-(2-Aminophenylamino)-4'-(trifluoromethyl)benzophenone (Compound 122)

General procedure 4

Starting compound II: 222

5 Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

Mp: 83-85°C

¹H NMR (CDCl₃): δ 3.80 (bs, 2H), 5.76 (bs, 1H), 6.65-6.85 (m, 4H), 7.12 (m, 2H), 7.65-7.85 (m, 6H)

10

Example 23N-(2-(4-Benzoylphenylamino)phenyl)ethanesulfonamide (Compound 123)

General procedure 5

Starting compound I: 101

Mp: 174-175 °C

15 ¹H NMR (DMSO-d₆): δ 1.12 (t, 3H), 3.01 (q, 2H), 6.96 (d, 2H), 7.15 (dt, 1H), 7.24 (dt, 1H), 7.42 (dt, 2H), 7.50-7.70 (m, 7H), 8.17 (s, 1H), 9.03 (bs, 1H)

Example 24N-(2-(4-Benzoylphenylamino)phenyl)benzenesulfonamide (Compound 124)

20 General procedure 5

Starting compound I: 101

Mp: 175-177 °C

¹H NMR (DMSO-d₆): δ 6.69 (d, 2H), 7.03 (t, 1H), 7.15-7.45 (m, 6H), 7.53-7.70 (m, 9H), 7.99 (s, 1H), 9.59 (s, 1H)

25

Example 25N-(4-(4-Benzoylphenylamino)phenyl)methanesulfonamide (Compound 125)

General procedure 5

Starting compound I: 101

^1H NMR (DMSO- d_6): δ 2.96 (s, 3H), 7.05 (d, 2H), 7.20 (s, 4H), 7.50-7.70 (m, 7H), 8.86 (s, 1H), 9.54 (bs, 1H)

Example 26

5 *N*-(2-(4-Benzoylphenylamino)phenyl)methanesulfonamide (Compound 126)

General procedure 5

Starting compound I: 101

Mp: 146-148 °C

10 ^1H NMR (DMSO- d_6): δ 2.92 (s, 3H), 6.99 (d, 2H), 7.17 (dt, 1H), 7.25 (dt, 1H),
7.43 (m, 2H), 7.50-7.70 (m, 7H), 8.17 (s, 1H), 9.03 (bs, 1H)

Example 27

N-(2-(4-Benzoylphenylamino)phenyl)-4-toluenesulfonamide (Compound 127)

General procedure 5

15 Starting compound I: 101

Mp: 194-195 °C

^1H NMR (DMSO- d_6): δ 2.10 (s, 3H), 6.62 (d, 2H), 7.00-7.70 (m, 15H), 7.95 (s, 1H), 9.47 (bs, 1H)

20

Example 28

1-(2-(4-Benzoylphenylamino)phenyl)-3-phenylurée (Compound 128)

To a solution of 4-(2-aminophenylamino)benzophenone (Compound 101, 0.58 g, 2 mmol) in toluene (10 ml) was added phenylisocyanate (0.22 ml, 2 mmol). The reaction mixture was heated for 20 hours on a steam bath. After cooling the reaction mixture to room temperature the resulting precipitate was collected by filtration and washed with toluene. The crude product was dissolved in hot isopropanol and crystallized on the addition of water to afford the title compound.

25

Mp: 154-156 °C

^1H NMR (DMSO-d_6): δ 6.79 (d, 2H), 6.95 (t, 1H), 7.06 (dt, 1H), 7.20 (dt, 1H), 7.24 (m, 3H), 7.43 (d, 2H), 7.47 (m, 2H), 7.66 (m, 5H), 8.09 (dd, 1H), 8.18 (s, 1H), 8.35 (s, 1H), 9.21 (s, 1H)

5

Example 29N-(2-(4-Benzoylphenylamino)phenyl)acetamide (Compound 129)

4-(2-Aminophenylamino)benzophenone (Compound 101, 0.58 g, 2 mmol) was dissolved in acetic anhydride (10 ml) and the solution was stirred at room temperature for 3 hours. The precipitate that forms after 75 min was filtered off and washed with water to afford the title compound.

10

Mp: 155-157 °C

^1H NMR (DMSO-d_6): δ 2.03 (s, 3H), 6.90 (d, 2H), 7.07-7.20 (m, 2H), 7.36 (dd, 1H), 7.50-7.70 (m, 8H), 8.17 (s, 1H), 9.45 (bs, 1H)

15

Example 304-(2-Aminophenylamino)benzophenone oxime (Compound 130)

To a solution of 4-(2-aminophenylamino)benzophenone (compound 101, 0.58 g, 2 mmol) and hydroxylamine hydrochloride (0.42 g, 6 mmol) in ethanol (30 ml) was added sodium acetate (0.49 g, 6 mmol). The reaction mixture was refluxed for 30 hours, cooled to room temperature, filtered, and evaporated *in vacuo*. The residue was treated with water (10 ml) and diluted ammonium hydroxide (5 ml). The precipitate that forms was filtered off, washed with water and dried to afford the title compound.

20

Mp: 89-91 °C

^1H NMR (DMSO-d_6): δ 4.75 (bs, 1H), 4.79 (bs, 1H), 6.50-7.50 (m, 14H), 10.8 (s, 0.5H), 11.10 (bs, 0.5H)

25

Example 314-(2-Aminophenylamino)benzophenone O-methyloxime (Compound 131)

To a solution of 4-(2-aminophenylamino)benzophenone (Compound 101, 0.29

ml) was added sodium acetate (0.30 g, 4 mmol). The reaction mixture was refluxed for 25 hours, cooled to room temperature, filtered, and evaporated *in vacuo*. The residue was treated with diluted ammonium hydroxide (10 ml) and extracted with ethyl acetate (2x25 ml). The organic phase was dried (MgSO₄), filtered and evaporated *in vacuo*. The residue was dissolved in diethyl ether and acidified with hydrochloric acid in diethyl ether. The hydrochloride of the title compound instantaneously precipitate. The precipitate was triturated with ethyl acetate and washed with diethyl ether to yield the title compound as a hydrochloride.

10 Mp: 186-187°C (as hydrochloride)

¹H NMR (DMSO-d₆): (as hydrochloride) δ 3.88 + 3.82 (2s, 3H), 6.90-7.50 (m, 13H), 8.61 (bs, 3H), 9.75 (vbs, 1H)

Example 32

15 Ethyl N-(2-(4-benzoylphenylamino)phenyl)carbamate (Compound 132)

General procedure 6, but replacing methyl iodide with ethyl chloroformate

Starting compound I: 101

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

Mp: 112-114 °C

20 ¹H NMR (DMSO-d₆): δ 1.20 (t, 3H), 4.09 (q, 2H), 6.87 (d, 2H), 7.13 (m, 2H), 7.32 (m, 1H), 7.50-7.70 (m, 8H), 8.20 (s, 1H), 8.75 (s, 1H)

Example 33

Ethyl 2-(2-(4-benzoylphenylamino)phenylamino)acetate (Compound 133)

25 General procedure 6, but replacing methyl iodide with ethyl bromoacetate

Starting compound I: 101

Purification: Chromatography using ethyl acetate/pentane 3:7 as eluant

Mp: 152-156 °C (as hydrochloride)

^1H NMR (DMSO- d_6): (as hydrochloride) δ 1.18 (t, 3H), 3.96 (s, 2H), 4.10 (q, 2H), 6.58 (d, 1H), 6.65-6.80 (m, 3H), 7.07 (m, 2H), 7.45-7.65 (m, 7H), 7.70 (vbs, 3H)

5

Example 344-(2-(Methylamino)phenylamino)benzophenone (Compound 134)

General procedure 6

Starting compound I: 101

Mp: 131-133 °C

10

^1H NMR (DMSO- d_6): δ 2.72 (d, 3H), 5.06 (q, 1H), 6.55-6.72 (m, 4H), 7.08 (m, 2H), 7.45-7.65 (m, 7H), 8.02 (s, 1H)

Example 354-(2-(Dimethylamino)phenylamino)benzophenone (Compound 135)

15

General procedure 6, but using 5 mmol methyl iodide

Starting compound I: 101

Mp: 99-101

^1H NMR (DMSO- d_6): δ 2.63 (s, 6H), 6.95-7.12 (m, 5H), 7.27 (dd, 1H), 7.50-7.67 (m, 7H), 8.18 (s, 1H)

20

Example 364'-(2-Aminophenylamino)-3,4,5-trimethoxybenzophenone (Compound 136)

General procedure 4

Starting compound II: 223

Purification: Chromatography using ethyl acetate/pentane 1:4 followed by 1:1 as eluant

25

Mp: sublimate at 60 °C

^{13}C NMR (CDCl $_3$): δ 194.3, 152.8, 150.0, 142.8, 141.2, 134.0, 132.7, 127.8, 127.4, 126.8, 125.9, 119.1, 116.4, 113.2, 107.3, 61.0, 56.3

Example 37N-(2-Aminophenyl)-N-methyl-4-aminobenzophenone (Compound 137)

General procedure 3

5 Starting compound II: 224

Purification: Crystallization from diethylether as hydrochloride

Mp: 169-172 °C

¹H NMR (DMSO-d₆): δ 8.5-5.5 (bs, 3H), 7.63 (m, 4H), 7.52 (m, 2H), 7.36 (bd, 2H), 7.23 (m, 3H), 6.64 (d, 2H), 3.26 (s, 3H)

10

Example 384'-(2-Aminophenylamino)-2'-methylbenzophenone (Compound 138)

General procedure 4

Starting compound II: 225

15 Purification: Trituration from diethyl ether

Mp: 168-170 °C

¹³C NMR (CDCl₃): δ 197.0, 150.5, 142.8, 139.7, 135.8, 132.7, 130.6, 129.4, 128.1, 127.6, 127.4, 126.8, 125.6, 125.1, 119.1, 116.3, 113.2, 19.7

20

Example 394'-(2-Aminophenylamino)-3,4-ethylenedioxybenzophenone (Compound 139)

General procedure 4

Starting compound II: 227

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

25 Mp: 168-170 °C

¹³C NMR (DMSO-d₆): δ 192.0, 150.7, 146.4, 143.6, 142.8, 131.9, 131.6, 125.9, 125.6, 124.9, 123.0, 118.1, 116.6, 116.3, 115.4, 112.4, 64.3, 63.9

Example 404-(2-Aminophenylamino)-2,4'-dichlorobenzophenone (Compound 140)

General procedure 4

Starting compound II: 228

5 Purification: Trituration from diethyl ether

^{13}C NMR (CDCl_3): δ 193.7, 149.2, 142.9, 139.3, 136.3, 134.1, 132.3, 131.4,
128.7, 127.7, 127.4, 126.9, 125.4, 119.2, 116.4, 115.1, 112.0

Example 4110 4'-(2-Aminophenylamino)-2,4-dichlorobenzophenone (Compound 141)

General procedure 4

Starting compound II: 226

Purification: Trituration from diethyl ether

15 ^{13}C NMR (CDCl_3): δ 192.3, 151.1, 142.8, 137.8, 135.8, 132.7, 132.1, 129.8,
129.8, 127.7, 127.0, 126.9, 126.7, 125.3, 119.1, 116.4, 113.3

Example 424-(2-Aminophenylamino)-4'-(1-methylbutyloxy)benzophenone (Compound 142)

General procedure 4

20 Starting compound II: 229

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 194.2, 161.4, 149.5, 142.8, 132.5, 132.1, 130.7, 128.5,
127.2, 126.6, 126.2, 119.1, 116.3, 114.8, 113.2, 73.7, 38.5, 19.7, 18.7, 14.0

25

Example 434-(2-Aminophenylamino)-3'-(trifluoromethyl)benzophenone (Compound 143)

General procedure 4

Starting compound II: 232

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 193.6, 150.5, 142.9, 139.6, 132.9, 132.6, 130.7, 128.7, 127.9, 127.6, 127.0, 126.9, 126.2, 125.6, 123.8, 119.2, 116.4, 113.3.

Example 44

5 4'-(2-Aminophenylamino)-2,3-dimethoxybenzophenone (Compound 144)

General procedure 4

Starting compound II: 230

Purification: Crystallization from methanol

10 ^{13}C NMR (CDCl_3): δ 194.3, 152.7, 150.4, 146.5, 142.8, 135.1, 132.6, 128.1, 127.3, 126.8, 125.7, 123.9, 120.3, 119.1, 116.3, 113.6, 113.1, 61.8, 55.9

Example 45

4-(2-Aminophenylamino)-3'-butoxybenzophenone (Compound 145)

General procedure 4

15 Starting compound II: 231

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 195.1, 159.0, 150.0, 142.8, 140.1, 132.8, 129.0, 127.9, 127.3, 126.8, 125.9, 122.0, 119.1, 118.3, 116.4, 114.8, 113.2, 67.9, 31.3, 19.2, 13.8

20

Example 46

4-(2-Aminophenylamino)-4'-ethoxybenzophenone (Compound 146)

General procedure 4

Starting compound II: 235

25 Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 194.2, 162.0, 149.5, 142.8, 132.5, 132.0, 131.0, 128.5, 127.2, 126.6, 126.2, 119.1, 116.3, 113.8, 113.2, 63.7, 14.7

Example 474'-(2-Aminophenylamino)-3,5-dichlorobenzophenone (Compound 147)

General procedure 4

Starting compound II: 233

5 Purification: Crystallization from ethanol

^{13}C NMR (DMSO- d_6): δ 190.4, 151.7, 143.7, 142.2, 134.1, 132.4, 130.3,
127.1, 126.3, 125.9, 124.4, 124.0, 116.3, 115.5, 112.6

Example 4810 4-(2-Aminophenylamino)-4'-benzyloxybenzophenone (Compound 148)

General procedure 4

Starting compound II: 234

Purification: Crystallization from ethanol

^{13}C NMR (CDCl_3): δ 194.1, 161.7, 149.6, 142.8, 136.4, 132.5, 132.0, 131.4,
15 128.7, 128.4, 128.2, 127.5, 127.2, 126.6, 126.1, 119.1, 116.3, 114.2, 113.2, 70.1

Example 494'-(2-Aminophenylamino)-3-methoxy-4-methylbenzophenone (Compound 149)

General procedure 4

20 Starting compound II: 237

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 195.0, 157.7, 149.8, 142.8, 137.5, 132.7, 131.1, 129.8,
128.2, 127.3, 126.7, 126.0, 122.6, 119.1, 116.3, 113.2, 110.6, 55.4, 16.4

25

Example 504-(4-Amino-2-chlorophenylamino)benzophenone (Compound 150)

General procedure 3

Starting compound II: 236

Purification: Chromatography using ethyl acetate/pentane 3:7 as eluant

^1H NMR ($\text{DMSO}-d_6$): δ 8.25 (bs, 1H), 7.69-7.55 (m, 5H), 7.51 (m, 2H), 7.04 (d, 1H), 6.74 (d, 1H), 6.63 (m, 2H), 6.57 (dd, 1H), 5.40 (bs, 2H)

Example 51

5 4-(2-Aminophenylamino)-4'-methoxybenzophenone (Compound 151)

General procedure 4

Starting compound II: 239

Purification: Trituration from diethyl ether

10 ^{13}C NMR (CDCl_3): δ 194.2, 162.5, 149.6, 142.8, 132.5, 132.0, 131.2, 128.4, 127.2, 126.6, 126.1, 119.1, 116.3, 113.4, 113.2, 55.4

Example 52

4-(2-Aminophenylamino)-2-chlorobenzophenone (Compound 152)

General procedure 4

15 Starting compound II: 238

Purification: Trituration from diethyl ether

^{13}C NMR (CDCl_3): δ 194.9, 148.9, 142.9, 137.9, 134.1, 132.9, 132.3, 130.0, 128.3, 127.9, 127.5, 126.8, 125.6, 119.2, 116.4, 115.1, 111.9

20 Example 53

4-(2-Aminophenylamino)-3-methylbenzophenone (Compound 153)

General procedure 4

Starting compound II: 240

25 ^{13}C NMR (CDCl_3): δ 195.4, 148.2, 142.9, 138.9, 133.1, 131.4, 131.1, 129.6, 128.0, 127.6, 127.4, 127.2, 126.0, 121.9, 119.2, 116.3, 111.2, 17.5

Example 54

4-(2-Aminophenylamino)-3'-phenylbenzophenone (Compound 154)

General procedure 4

Purification: Chromatography using methylene chloride as eluant

^{13}C NMR (CDCl_3): δ 195.1, 150.0, 142.8, 141.1, 140.4, 139.4, 132.9, 130.1, 128.9, 128.6, 128.4, 128.2, 127.9, 127.7, 127.4, 127.2, 126.8, 125.8, 119.2, 116.4, 113.2

5

Example 55

4-(2-Aminophenylamino)-2'-phenylbenzophenone (Compound 155)

General procedure 4

Starting compound II: 241

10

Purification: Crystallization from methylene chloride

Mp: 195-196 °C

^{13}C NMR ($\text{DMSO}-d_6$): δ 194.9, 151.1, 143.5, 140.1, 139.5, 139.5, 131.8, 129.8, 129.4, 128.4, 128.2, 127.7, 127.0, 126.9, 126.0, 125.8, 125.6, 124.6, 116.3, 115.4, 112.3

15

Example 56

4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone (Compound 156)

General procedure 4

Starting compound II: 243

20

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant followed by trituration from diethyl ether

Mp: 113-116 °C

^{13}C NMR (CDCl_3): δ 196.5, 149.5, 142.9, 139.3, 137.7, 135.2, 133.7, 131.2, 130.7, 129.5, 128.2, 127.7, 126.9, 125.3, 119.2, 116.4, 115.3, 111.8, 20.4

25

Example 57

4-(2-Aminophenylamino)-4'-phenylbenzophenone (Compound 157)

General procedure 4

Starting compound II: 245

Mp: 179-182 °C

¹³C NMR (DMSO-d₆): δ 193.0, 151.0, 143.6, 142.8, 139.1, 137.4, 132.1, 129.7, 129.0, 128.0, 126.8, 126.4, 126.0, 125.7, 125.3, 124.8, 116.3, 115.4, 112.5

5

Example 58

4-(2-Amino-5-hydroxyphenylamino)benzophenone (Compound 158)

General procedure 3

Starting compound II: 266

10

Purification: Crystallized from ether as hydrochloride

Mp: > 240 °C (as hydrochloride)

¹H NMR (DMSO-d₆): (as hydrochloride) δ 9.98 (bs, 2H), 9.87 (bs, 2H), 9.01 (s, 1H), 7.75-7.59 (m, 5H), 7.54 (m, 2H), 7.28 (d, 1H), 7.05 (m, 2H), 6.91 (d, 1H), 6.61 (dd, 1H)

15

Example 59

4-(2-Aminophenylamino)-2'-hydroxybenzophenone (Compound 159)

General procedure 4

Starting compound II: 247

20

Purification: Crystallization from diethyl ether

¹³C NMR (CDCl₃): δ 199.3, 162.7, 149.8, 142.9, 135.4, 133.1, 132.3, 128.0, 127.4, 126.8, 125.8, 119.7, 119.2, 118.4, 118.2, 116.4, 113.3

Example 60

25 4-(4-Aminophenylamino)-2'-methylbenzophenone (Compound 160)

General procedure 4

Starting compound II: 246

Purification: Chromatography using ethyl acetate/pentane 1:1 as eluant followed by trituration from diethyl ether

^{13}C NMR (CDCl_3): δ 196.9, 151.1, 143.9, 139.9, 135.8, 132.7, 130.9, 130.6, 129.3, 127.6, 125.4, 125.1, 115.9, 112.8, 19.7

Example 61

5 4-(2-Aminophenylamino)-3'-cyanobenzophenone (Compound 161)

General procedure 4

Starting compound II: 244

Purification: Chromatography using ethyl acetate/pentane 1:1 as eluant followed by trituration from methylene chloride

10 Mp: 146-149 °C

^{13}C NMR (CDCl_3): δ 192.6, 150.8, 142.9, 140.0, 134.5, 133.4, 133.0, 132.9, 129.2, 127.7, 127.0, 126.5, 125.4, 119.2, 118.2, 116.4, 113.4, 112.5

Example 62

15 4-(2-Aminophenylamino)-2'-phenoxymethylbenzophenone (Compound 162)

General procedure 4

Starting compound II: 249

Purification: Trituration from diethyl ether

Mp: 156-159 °C

20 ^{13}C -NMR (CDCl_3): δ 195.9, 158.5, 150.5, 142.8, 138.4, 136.3, 132.9, 130.0, 129.3, 128.4, 128.2, 128.1, 127.5, 127.0, 126.8, 125.7, 120.9, 119.2, 116.4, 114.9, 113.2, 67.4

Example 63

25 4-(2-Aminophenylamino)-2'-bromobenzophenone (Compound 163)

General procedure 4

Starting compound II: 250

Mp: 156-161 °C

^{13}C NMR (CDCl_3): δ 194.0, 150.9, 142.8, 141.5, 133.0, 132.9, 130.5, 128.6,

Example 644'-(2-Aminophenylamino)-2,3,5,6-tetramethylbenzophenone (Compound 164)

General procedure 4

Starting compound II: 251

5 ^{13}C NMR (CDCl_3): δ 199.7, 150.6, 142.8, 140.5, 134.0, 132.0, 131.4, 129.6,
128.6, 127.4, 126.9, 125.7, 119.1, 116.3, 113.4, 19.5, 16.3

Example 654-(2-Aminophenylamino)-2'-ethylbenzophenone (Compound 165)

10 General procedure 4

Starting compound II: 248

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 197.1, 150.5, 142.8, 142.2, 139.4, 132.7, 129.5, 129.1,
128.4, 127.6, 127.4, 126.9, 125.7, 125.1, 119.1, 116.4, 113.2, 26.3, 15.8

15

Example 664-(3-Aminophenylamino)benzophenone (Compound 166)

General procedure 4

Starting compound II: mangler

20 Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 195.2, 148.2, 147.7, 141.7, 138.7, 132.7, 131.5, 130.3,
129.6, 128.5, 128.1, 114.6, 110.8, 110.3, 106.9

Example 67

25 4-(4-Aminophenylamino)-2'-hydroxybenzophenone (Compound 167)

General procedure 4

Starting compound II: mangler

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 199.1, 162.6, 150.5, 143.8, 135.2, 133.1, 132.4, 131.1,

Example 684-(2-Aminophenylamino)-2',3-dimethylbenzophenone (Compound 168)

General procedure 4

Starting compound II: 253

5 Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

^{13}C NMR (CDCl_3): δ 197.3, 148.7, 142.9, 139.8, 135.9, 132.7, 131.1, 130.6, 129.3, 128.0, 127.7, 127.5, 127.3, 125.8, 125.1, 121.9, 119.2, 116.4, 111.3, 19.7, 17.5

10

Example 694-(2-Aminophenylamino)-3-methoxy-2'-methylbenzophenone (Compound 169)

General procedure 4

Starting compound II: 252

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

15 ^{13}C NMR (CDCl_3): δ 197.1, 146.6, 142.9, 140.8, 139.8, 135.8, 130.6, 129.3, 127.6, 127.5, 127.4, 127.2, 126.9, 125.4, 125.0, 119.0, 116.2, 109.9, 109.6, 55.8, 19.7

Example 7020 4-(2-Aminophenylamino)-2-methoxy-2'-methylbenzophenone (Compound 170)

To a solution of 2-methoxy-2'-methyl-4-(2-nitrophenylamino)benzophenone (Compound 255, 1.02 g, 2.8 mmol) in methanol (10 ml) was added, under argon, ammonium formate (0.80 g, 13 mmol) and 10 % palladium on carbon (0.16 g). The reaction mixture was stirred at room temperature for 16 hours. The mixture was filtered
25 through Celite® and evaporated *in vacuo*. The residue was treated with water (50 ml) and extracted with methylene chloride (2x50 ml). The organic phase was dried (MgSO_4), filtered and evaporated *in vacuo* to afford the crude product which was further purified by chromatography using ethyl acetate/pentane 1:1 as eluant.

Mp: 122-125 °C

^{13}C NMR (CDCl_3): δ 196.5, 161.8, 151.4, 142.8, 141.8, 135.9, 134.9, 130.5, 129.2, 127.9, 127.3, 126.7, 125.8, 125.0, 119.1, 119.0, 116.4, 105.9, 97.0, 55.5, 19.9

Example 71

4-(2-Aminophenylamino)-2'-tert-butoxybenzophenone (Compound 171)

By following the procedure of example 70, but using 2-tert-butoxy-4'-(2-nitrophenylamino)benzophenone (Compound 256) in place of 2-methoxy-2'-methyl-4-(2-nitrophenylamino)benzophenone (Compound 255), the desired compound was obtained.

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 195.7, 153.3, 149.9, 142.6, 135.7, 132.5, 130.4, 129.4, 128.9, 127.1, 126.5, 126.1, 123.0, 122.8, 119.1, 116.4, 113.1, 80.1, 28.9

Example 72

4-(2-Aminophenylamino)-2-chloro-2'-(trifluoromethyl)benzophenone (Compound 172)

General procedure 4

Starting compound II: 257

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

Mp: 128-129 °C

^{13}C NMR (CDCl_3): δ 192.8, 150.6, 143.0, 140.2, 136.7, 135.3, 131.4, 129.8, 128.4, 128.0, 128.0, 127.2, 126.8, 125.6, 124.7, 123.7, 119.2, 116.5, 115.5, 111.6

Example 73

Ethyl N-(2-(4-(2-methylbenzoyl)-3-chlorophenylamino)phenyl)carbamate (Compound 173)

General procedure 6, but replacing methyl iodide with ethyl chloroformate

Starting compound I: 156

^{13}C NMR (CDCl_3): δ 196.6, 154.1, 149.1, 139.1, 138.0, 135.0, 133.5, 133.4, 131.3, 130.9, 130.5, 129.7, 129.2, 126.9, 126.0, 125.4, 124.9, 121.7, 116.1, 112.5, 61.7, 20.5, 14.5

5

Example 744'-(2-Aminophenylamino)-3'-chloro-4-methoxy-2,6-dimethylbenzophenone (Compound 174)

General procedure 4

Starting compound II: 259

10

Purification: Crystallization from diethyl ether

Mp: 158-159 °C

^{13}C NMR (CDCl_3): δ 197.1, 159.6, 150.1, 142.9, 136.6, 136.0, 134.6, 134.0, 127.8, 127.2, 127.0, 125.0, 119.2, 116.4, 115.9, 113.1, 111.8, 55.1, 20.0

15

Example 754-(4-Aminophenylamino)-2-chloro-2'-methylbenzophenone (Compound 175)

General procedure 4

Starting compound II: 261

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

20

^{13}C NMR ($\text{DMSO}-d_6$): δ 194.8, 151.2, 145.9, 139.8, 135.9, 134.0, 134.0, 130.8, 130.2, 128.3, 128.1, 125.5, 124.6, 124.4, 114.5, 113.5, 110.5, 19.5

Example 764-(2-Aminophenylamino)-2'-allyloxybenzophenone (Compound 176)

25

General procedure 4

Starting compound II: 254

Purification: Chromatography using ethyl acetate/pentane 1:4 followed by 1:2 as eluant

^{13}C NMR (CDCl_3): δ 194.6, 155.9, 150.1, 142.7, 132.9, 132.5, 130.9, 130.2,

Example 774-(2-Amino-4-methylphenylamino)-2-chloro-2'-methylbenzophenone (Compound 177)

General procedure 4

Starting compound II: 260

5 ^{13}C NMR (CDCl_3): δ 195.7, 150.0, 142.9, 139.5, 137.9, 137.7, 135.3, 133.8,
131.2, 130.6, 129.5, 128.0, 127.3, 125.3, 122.5, 120.0, 116.9, 115.1, 111.5,
21.2, 20.4

Example 78

10 4-(2-Aminophenylamino)-2-chloro-2'-methoxybenzophenone (Compound 178)

General procedure 4

Starting compound II: 262

Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

Mp: 67-69 °C

15 ^{13}C NMR (CDCl_3): δ 193.7, 158.1, 149.2, 142.8, 135.0, 133.6, 132.5, 130.4,
129.9, 128.7, 127.5, 126.7, 125.5, 120.5, 119.1, 116.4, 115.2, 111.8, 111.6, 55.9

Example 793-Allyl-4'-(2-aminophenylamino)-2-hydroxybenzophenone (Compound 179)

20 General procedure 4

Starting compound II: 258

Purification: Chromatography using ethyl acetate/pentane 1:9 as eluant

^{13}C NMR ($\text{DMSO}-d_6$): δ 197.5, 158.1, 151.2, 143.8, 136.4, 134.6, 132.2,
130.2, 128.3, 126.2, 125.9, 125.5, 124.8, 120.7, 118.5, 116.5, 116.0, 115.5,
25 112.5, 33.2

Example 804'-(2-Aminophenylamino)-2'-chloro-2,4,5-trifluorobenzophenone (Compound 180)

General procedure 4

Starting compound II: 263

Purification: Chromatography using ethyl acetate/pentane 1:3 as eluant

^{13}C NMR (CDCl_3): δ 184.3, 154.9, 151.1, 147.5, 147.0, 143.0, 136.5, 134.8, 128.1, 127.3, 125.7, 124.4, 120.7, 119.2, 118.4, 116.5, 115.5, 112.0, 111.4

5

Example 81

2,2,2-Trifluoro-N-(2-(4-(2-methylbenzoyl)-3-chlorophenylamino)phenyl)acetamide (Compound 181)

To a cold (ice/water) solution of 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone (Compound 156, 1.0 g, 3.0 mmol) and pyridine (0.4 ml, 4.5 mmol) in methylene chloride (10 ml) was added trifluoroacetic acid anhydride (0.46 ml, 1.1 mmol). After stirring for 30 minutes, the reaction mixture was poured into water and, extracted with ethyl acetate (2x50 ml). The organic phase was dried (MgSO_4), filtered and evaporated to afford the almost pure product.

15 Purification: Chromatography using ethyl acetate/pentane 1:2 as eluant

^{13}C NMR (CDCl_3): δ 196.8, 155.2, 148.5, 138.6, 138.2, 134.9, 133.3, 131.8, 131.4, 131.2, 130.9, 130.2, 129.9, 127.6, 127.3, 126.4, 125.4, 122.9, 116.5, 15.6, 112.9, 20.5

20

Example 82

4-(2-Aminophenylamino)-2-chloro-2',6'-dimethylbenzophenone (Compound 182)

General procedure 4

Starting compound II: 264

Purification: Chromatography using ethyl acetate/pentane 1:4 as eluant

25 Mp: 139-140 °C

^{13}C NMR (CDCl_3): δ 197.2, 150.4, 142.9, 141.1, 136.3, 135.0, 134.2, 128.6, 127.9, 127.6, 127.1, 126.0, 124.8, 119.1, 116.4, 116.1, 111.7, 19.5

Example 834-(2-Aminophenylamino)-2-chloro-4'-fluoro-2'-methylbenzophenone (Compound 183)

General procedure 4

Starting compound II: 265

5 Purification: Chromatography using ethyl acetate/pentane 1:3 as eluant

Mp: 152-154 °C

^{13}C NMR (CDCl_3): δ 195.3, 163.9, 149.5, 142.9, 141.5, 135.4, 135.0, 133.4, 132.3, 128.4, 127.7, 126.9, 125.3, 119.2, 118.1, 116.4, 115.3, 112.3, 111.9, 20.7

10

Example 843-(2-(4-(2-Methylbenzoyl)-3-chlorophenylamino)phenyl)-1,1-dimethylurea (Compound 184)

A mixture of 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone (Compound 156, 1.2 g, 3.5 mmol), dimethylcarbamyl chloride (0.32 ml, 3.5 mmol) and
15 potassium carbonate (1.0 g, 7 mmol) in *N,N*-dimethylformamide (20 ml) was stirred at room temperature for 16 hours. The reaction mixture was poured into water (100 ml) and was extracted with ethyl acetate (3x75 ml). The organic phase was dried (MgSO_4), filtered and evaporated *in vacuo* to give the crude product. The crude product was
20 purified by flash chromatography by using ethyl acetate/pentane mixtures from 1:9 to 1:1. Trituration with diethyl ether/pentane 1:1 afforded the pure title compound.

^{13}C NMR (CDCl_3): δ 196.3, 150.9, 149.9, 139.8, 138.8, 136.6, 136.4, 133.1, 132.3, 132.0, 131.6, 131.0, 129.1, 127.6, 127.3, 125.7, 123.8, 123.4, 112.7, 109.0, 38.8, 37.1, 21.3

25

Example 854-(2-(n-Butylamino)phenylamino)benzophenone (Compound 185)

General procedure 6, but using n-butybromide in isopropanol under reflux

Starting compound I: 101

Purification: Chromatography using ethyl acetate/pentane 3:7 as eluant

Mp: 88-93 °C

¹H NMR (DMSO-d₆): δ 8.03 (bs, 1H), 7.69-7.55 (m, 5H), 7.51 (m, 2H), 7.07 (m, 2H), 6.76-6.66 (m, 3H), 6.60 (m, 1H), 4.75 (t, 1H), 3.07 (q, 2H), 1.51 (m, 2H), 1.33 (m, 2H), 0.88 (t, 3H)

5

Example 86

N-(4-Benzoylphenyl)-N,N'-1,2-phenylene-di(2,2,2-trifluoroacetamide) (Compound 186)

To a solution of 4-(2-aminophenylamino)benzophenone (Compound 101, 0.29 g, 1.0 mmol) and pyridine (0.25 ml, 3.0 mmol) in methylene chloride (10 ml) was added trifluoroacetic acid anhydride (0.30 ml, 2.2 mmol). After stirring for 45 minutes at room temperature, the reaction mixture was evaporated *in vacuo*. The residue crystallized on trituration with water (10 ml) to afford the title compound after filtration.

10

¹H NMR (DMSO-d₆): δ 11.5-11.1 (bs, 1H), 7.95-7.37 (m, 13H)

15

Example 87

2,2,2-Trifluoro-N-(2-(4-benzoylphenylamino)phenyl)acetamide (Compound 187)

By following the procedure of example 81, but using 4-(2-aminophenylamino)-benzophenone (Compound 101) in place of 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone (Compound 156), the desired compound was obtained.

20

Purification: Trituration from diethyl ether

Mp: 187-191 °C

¹H NMR (DMSO-d₆): δ 10.80 (bs, 1H), 8.47 (s, 1H), 7.71-7.58 (m, 5H), 7.53 (m, 2H), 7.43 (m, 2H), 7.33 (m, 1H), 7.17 (m, 1H), 6.93 (m, 2H)

25

Example 88

1-(2-(4-Benzoylphenylamino)phenyl)-3-n-propylurea (Compound 188)

To a solution of 4-(2-aminophenylamino)benzophenone (Compound 101, 0.58 g, 2 mmol) in toluene (10 ml) was added n-propylisocyanate (0.23 ml, 2.4 mmol). The reaction mixture was heated for 4 hours on a steam bath. After cooling the reaction

washed with toluene. The crude product was dissolved in hot isopropanol and crystallized on cooling to afford the title compound.

Mp: 167-169 °C

¹H NMR (DMSO-d₆): δ 8.25 (s, 1H), 8.03 (m, 1H), 7.86 (s, 1H), 7.70-7.56 (m, 5H), 7.51 (m, 2H), 7.81 (m, 1H), 7.12 (m, 1H), 6.97 (m, 1H), 6.75 (m, 3H), 3.02 (q, 2H), 1.41 (m, 2H), 0.85 (t, 3H)

Example 89

N-(2-(4-Benzoylphenylamino)phenyl)formamide (Compound 189)

10 A solution of 4-(2-aminophenylamino)benzophenone (Compound 101, 0.29 g, 1.0 mmol) in ethyl formate (5.0 ml, 63 mmol) was refluxed for 16 hours. The reaction mixture was evaporated *in vacuo* and dissolved in ethyl acetate. The solution was filtered and evaporated *in vacuo*. The residue was crystallized on the addition of diethyl ether to afford the pure title compound.

15 Mp: 122-124 °C


¹³C NMR (DMSO-d₆): δ 194.6, 144.0, 143.1, 139.3, 136.8, 135.6, 132.8, 132.5, 131.5, 129.6, 128.6, 123.7, 123.0, 122.8, 120.1, 110.9

Example 90: Creme formulation

20 4-(2-Aminophenylamino)benzophenone (Compound 101, 10 g) was dissolved in diethyleneglycolmonoethylether (350 g) and distilled water (350 g) was added. Methylparaben (1 g) and propylparaben (0.2 g) were dissolved in phenoxyethanol (6 g). This solution was mixed with the former solution of Compound 101. Paraffin oil (183 g), cetostearyl alcohol (50 g) and ARLACEL[®] (50 g) was melted in a vessel at 70 to 25 80 °C. The mixed solutions were likewise heated to 60-70 °C and slowly added to the melted oil phase under high speed stirring. The homogenized components were cooled to room temperature.

WHAT WE CLAIM IS:

1. A compound of the formula I



I

- 5 in which formula R_1 and R_2 stands independently for one or more, similar or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxy carbonyl, the C-content of which can be from 1 to 5, cyano, carboxy, carbamoyl, phenyl, or nitro; R_3 stand for hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, alkyl, alkoxy, alkylthio, alkylamino, or alkoxy carbonyl, the C-content of which
 10 can be from 1 to 5, phenyl, cyano, carboxy, or carbamoyl; R_4 , R_5 and R_6 stands independently for hydrogen, trifluoromethyl, alkyl, carbamoyl, alkoxy carbonyl, or alkyloxy, the C-content of which can be from 1 to 5; X stands for oxygen, N-OH, N-O-alkyl, dialkoxy, cyclic dialkoxy, dialkylthio, or cyclic dialkylthio, the C-content of
 15 which can be from 1 to 5; and salts with pharmaceutically acceptable, non-toxic acids.

2. A compound according to formula I of claim 1, in which formula R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 have the meanings as defined in claim 1; X stands for oxygen, N-OH, or N-O-alkyl, the C-content of which can be from 1 to 5; and salts with
 20 pharmaceutically acceptable, non-toxic acids.

3. A salt according to claim 1 in which the salt is selected from the group consisting of salts formed with hydrochloric, hydrobromic and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, and maleic acid.

5

4. A compound of claim 1 which is selected from the group consisting of:

4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone;

4-(2-aminophenylamino)-2-methoxy-2'-methylbenzophenone;

4-(2-aminophenylamino)-2-chloro-2'-(trifluoromethyl)benzophenone;

10 ethyl *N*-(2-(4-(2-methylbenzoyl)-3-chlorophenylamino)phenyl)carbamate;

4'-(2-aminophenylamino)-3'-chloro-4-methoxy-2,6-dimethylbenzophenone;

2,2,2-trifluoro-*N*-(2-(4-(2-methylbenzoyl)-3-chlorophenylamino)phenyl)acetamide;

4-(2-aminophenylamino)-2-chloro-2',6'-dimethylbenzophenone; and

4-(2-aminophenylamino)-2-chloro-4'-fluoro-2'-methylbenzophenone;

15

and their salts.

5. A pharmaceutical preparation, containing a compound according to any one of claims 1 - 4 alone or together with the necessary auxiliary agents.

20




6. A method for the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, proliferative and inflammatory skin disorders, such as psoriasis, and atopic dermatitis, characterized in administering to said patients an effective amount of one or more compounds according to any of claims 1 - 4, if necessary together or concomitantly with one or more other therapeutically active components.

25


30

7. A method for producing a compound of formula I according to claim 1, in

- a) a compound of formula III is coupled with a compound of formula IVa or IVb in a solvent (e.g. dimethylsulfoxide) in the presence of base (e.g. potassium tert-butoxide) to give a product of the formula II



5



in which X, R₁, R₂, R₃, and R₆ are as defined in claim 1;

- b) a compound of formula II is reduced with an appropriate reducing agent (e.g. stannous chloride) to form the desired compound of formula I of claim 1.

10

8. The use of a compound of claim 1 in the manufacture of a medicament for the treatment and prophylaxis of asthma, allergy, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease,

psoriasis, and atopic dermatitis.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK 98/00008

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C225/22 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | GB 1 535 401 A (HOLLIDAY & CO LTD L) 13 December 1978 see claims 1,4; example 3 | 1,2 |
| X | DE 37 39 402 A (RICOH KK) 1 June 1988 see compounds of formula (Ia) | 1,2 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 April 1998

Date of mailing of the international search report

22.04.98

Name and mailing address of the ISA

Authorized officer

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/ 00008

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 6
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 98/00008

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| GB 1535401 A | 13-12-78 | NONE | |
| DE 3739402 A | 01-06-88 | JP 2049544 C | 10-05-96 |
| | | JP 7076303 B | 16-08-95 |
| | | JP 63130667 A | 02-06-88 |
| | | US 4880762 A | 14-11-89 |
| | | US 4981970 A | 01-01-91 |